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Abstract 
Cartilage is an aneural and avascular tissue, which is composed of 
chondrocytes, embedded within an extracellular matrix. Cartilage degradation, 
joint inflammation and bone destruction are the prominent features of 
rheumatoid arthritis, which is a persistent autoimmune disorder. Cartilage 
matrix is made up of collagen to provide tensile strength with aggregated 
proteoglycans to facilitate hydration. The loss of cartilage proteoglycans is 
among one of the early events in cartilage degradation associated with arthritic 
joint pathology. The pro-inflammatory cytokines such as Tumour Necrosis 
Factor alpha (TNF-a) and Interleukin-1 beta (IL-l~) have been shown to 
increase the loss of proteoglycans from cartilage and to modulate the 
production of nitric oxide (NO). NO has been associated with cartilage 
degradation. TNF-a and IL-l~ have also been reported to inhibit erythropoiesis 
thereby leading to the development of anaemia. Human recombinant 
erythropoietin (rHuEPO) is administered to treat anaemia of chronic disease, 
which is a well-known complication of chronic rheumatoid arthritis (RA). 
However, the effect ofEPO on cartilage metabolism in RA is yet unknown. 
The aim of current study was to investigate the effects of EPO on in vitro 
models of RA, which were developed with increasing order of complexity, 
with respect to the production of NO and release of proteoglycans. The 
production of NO was determined indirectly by measuring nitrite production, 
via Greiss reaction. The loss of cartilage proteoglycans was quantified by 
measuring the release of glycosaminoglycans (GAGs), using GAGs assay. 
4 
Each system was found to respond to IL-113 treatment. Thus, IL-113 was 
maintained as a positive control stimulus in these investigations. Swiss 3 T3 
fibroblast monolayer was utilised to model the response of rheumatoid synovial 
fibroblasts in pannus tissue of RA joint. An in vitro model of cartilage resorption 
was established using porcine cartilage explants. This model was then modified 
by incorporating Swiss 3 T3 fibroblasts mono layers with explants. 
These studies reveal that that EPO (25J..!U/ml) whether alone or in the presence of 
IL-113, is a pro-inflammatory stimulus of cartilage breakdown. There was no 
significant difference in the IL-l and EPO-mediated GAGs release and nitrite 
production by both explant and co-culture models, which suggests that EPO may 
be as potent stimulus as IL-l with regard to cartilage breakdown in these models 
of RA. The current investigation concludes that EPO can directly influence 
cartilage degradation and may potentiate joint inflammation in RA. Therefore, 
findings from this study suggest that clinical administration of EPO to treat 
anaemia and its illegal usage by athletes may lead to development of arthritis in 
later life. 
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CHAPTER 1: INTRODUCTION 
15 
1.0: General Introduction 
Inflammation is a normal physiological response that is induced by tissue damage 
or foreign tissue recognition by the immune system and is also associated with all 
rheumatic diseases. The purpose of the inflammatory response is to repair tissue 
damage, prevent further infection and remove any foreign material from an 
infected area (Benjamini, 1996). 
Arthritis is a persistent autoimmune disease with a variable incidence, involving 
chronic inflammation of the diarthroidal joints, which causes cartilage degradation 
and bone destruction (Mort et al., 2001; Evans et al., 1996). Arthritis 
encompasses all the rheumatic diseases that affect synovial joints and there are 
approximately 127 kinds of arthritis (Neil, 1993). The rheumatic diseases that 
affect articular joints can be broadly grouped into those that appear to be driven 
by inflammatory cascades, those associated with immune or autoimmune 
reactions, e.g. rheumatoid arthritis (RA) (see section 1.3), and those that are 
sustained by non-inflammatory mechanisms or occur as a result of degenerative 
changes, e.g. osteoarthritis (OA) (see section 1.2) (Hardingham et al., 1991). 
1.1: Epidemiological overview of RA 
The occurrence and manifestation of RA is geographically variable and it is 
estimated that worldwide, 1 in every 100 people suffers from RA (Hartzheim and 
Goss, 1998). In Western countries including UK, it affects 1-3% of the population 
with a 3:1 female preponderance (Abdel-Nasser et al., 1997; Hartzheim and Goss, 
1998). According to Abdel-Nasser et al., (1997), significantly higher rates of RA 
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are found in North American Indians, and significantly lower rates among Asians 
and Africans as compared to the white population of Europe and America. For 
those who suffer from this disease life span is decreased on average by 7. 5 years 
for men and 3.5 years for women (Mike, 1997). 
1.2: Osteoarthritis (OA) 
OA is a health problem of global significance due to its progressive and 
debilitating nature that results in a high morbidity and a marked decrease in the 
quality of life. OA, also referred to, as "degenerative joint disease" is the most 
common joint disease that is related to age and it is generally caused by the wear 
and tear that joints are subjected to over time. However, some chemical and 
genetic factors may also play a role in the development of the disease. Risk 
factors such as being overweight, poor posture, congenital joint or bone 
deformities and injury to a joint may hasten the development of OA in people 
under 60 years of age (Felson et al., 2000). 
OA is characterised by loss of focal cartilage with accompanymg bone 
deterioration and specific radiographic features involve joint space narrowing and 
the presence of osteophytes and sclerosis (Gold et al., 1988). 
1.3: Rheumatoid arthritis (RA) 
RA is an autoimmune chronic inflammatory disease of uncertain etiology that 
manifests itself by joint pain and swelling, rheumatoid nodules formation, 
synovial hyperemia, erosions of cartilage and inflammation. Extra-articular 
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manifestations of the disease can include weight loss, fever, arteritis and 
osteopenia. The most commonly involved joints are the proximal interphalangeal 
joints (the distal joints are spared); the metacarpophalangeal joints; the wrists, 
elbows, knees and ankles; and the metatarsophalangeal joints. (Mort and 
Billington, 2001). 
1.3.1: Comparison of OA and RA 
OA primarily affects single unilateral weight-bearing joints such as the knee or 
hip, whereas RA affects nonweight-bearing bilateral joints symmetrically, such as 
hands and wrists. The major features that distinguish OA from RA include 
radiographic evidence of osteophyte formation, and erythrocyte sedimentation rate 
(ESR) laboratory value less than 20 mm/hr. The ESR value higher than 25 mm/hr 
suggests inflammation. More specific to RA inflammation is the C-reactive 
protein (CRP), one of the acute phase reactants. CRP values higher than 3mg/dL 
suggest active inflammatory process (Wolfe 1997). 
Although both OA and RA differ in pathophysiology and the molecular 
mechanisms responsible for the destruction of cartilage, there are, however, a 
certain number of similarities and common pathways in the inflammatory 
processes of both diseases (Yatsugi et al., 2000). The inflammatory mediators 
involved in synovial joint and bone destruction have been identified in both 
complications and these mediators contribute to the changes from normal joint 
physiology (see section 1.4) to arthritic disease pathology (see section 1.5). 
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1.4: Normal joint physiology 
A normal joint is designed to perform a wide range of movements. Synovial 
joints, characterised by fluid filled cavities, are composed of various tissue 
components, joint capsule, synovium, articular cartilage, subchondral bone and 
ligaments, which provide different structural properties, that contribute to the 
overall function of the joint. The joint capsule is composed of an outer fibrous 
layer that is attached to the bone and the synovial membrane that lines the inner 
surface of the joint (see Fig. 1.4). 
Fig. 1.4: Diagram of a synovial joint tissue 
muscle bursa cartilage 
synovhtJ 
membrane 
Fig. 1.4: A diagram illustrating the components of a normal joint. Picture adapted 
from, Neil, F.N. (1993) Arthritis: Your complete exercise guide, Human Kinetics 
Publishers, South Australia. 
1.4.1: Synovial membrane 
Synovial membrane is a vascularised sheet of unattached fibrous tissue that is 
lined by mesenchymal cells, called synoviocytes. Synoviocytes have been 
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classified into two cell types; macrophage-derived phagocytes (Type A cells) that 
produce cartilage degrading enzymes and mesenchymal connective tissue lineage 
derived cells (Type B cells) that produce synovial fluid, which facilitates joint 
nourishment and lubrication (Freemont, 1996). Furthermore, fibroblast like cells, 
proteolytic enzymes and cholinase inhibitors are produced by synoviocytes. Thus, 
synoviocytes play an important role in the breakdown and repair of cartilage. 
1.4.2: Synovial fluid 
Synovial fluid covers the surfaces of joint as a thin lubricating film and becomes 
less viscous as it warms during the joint activity, nourishing and lubricating the 
articulating surfaces. The hyaline cartilage at these surfaces soaks up synovial 
fluid to become spongy cushions, which absorb compression. This prevents the 
bone ends from being crushed and provides smooth and load bearing surfaces for 
bones of the joint to move each other. 
Synovial fluid within a joint has three important functions, lubrication, nutrient 
distribution, and shock absorption. Synovial fluid contains a high concentration of 
proteoglycans secreted by fibroblasts of synovial membrane chondrocytes 
(Heinegard and Oldberg, 1989). 
1.4.3: Articular cartilage 
Articular cartilage is avascular, aneural and is composed of chondrocytes (Ober et 
al., 1998). Cartilage matrix, composed of collagen fibres, proteoglycans and 
water, is synthesised by chondrocytes. Proteoglycans are hydrophilic and play a 
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critical role in regulating the movement of water within the matrix and influence 
the mechanical and lubricant properties of cartilage (Heinegard and Sommarin, 
1987). 
1.4.3.1: Chondrocytes 
Chondrocytes are the cellular manufacturing sites of cartilage and are responsible 
for the production and maintenance of the surrounding matrix. Each chondrocyte 
is typically an ovoid structure although it can vary from a spheroidal to a flattened 
shape and the surface is irregular with projecting cell processes (see Fig. : 1.4.3.1). 
These variations are related to cartilage type, the position of the chondrocyte 
within the cartilage, and the maturity ofthe tissue (Neil, 1993). 
Fig.: 1.4.3.1: Chondrocytes in a cartilage matrix 
Fig.1.4.3.1: Chondrocytes embedded in cartilage matrix. Picture adapted from 
Microanatomy Web Atlas, 1998. 
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1.4.3.2: Collagen 
Collagens are a family of proteins that form a dense network of fine fibres, which 
contribute to the overall shape and structural properties of tissues. Fourteen types 
of collagen have been described and characterised so far, which are distinguished 
on the basis of their chemical differences. The most important types are the 
fibrillar collagen types I, II, Ill, IV and V. Type I collagen is the most abundant 
collagen and forms the largest and strongest fibrillar component that provides 
tensile strength to bones, skin, tendons and ligaments (Cremer et al. , 1998). 
Type III collagen is similar in structure to type I but less abundant and is often 
found in areas of rapid new collagen synthesis. Type IV is a major component of 
all basement membranes and type V is found in some veins and arteries. Articular 
cartilage collagen is 90% Type II collagen that provides tensile strength and 
stiffness and is composed of a triple helix made of three identical alpha chains. 
Large number of proline and hydroxyproline amino acids keep the alpha chains 
extended and stabilise the triple helix (Cremer et al. , 1998). 
1.4.3.3: Proteoglycans 
Proteoglycans, which are retained within the fibrous network of collagenous 
cartilage, are predominantly of large aggregating type that occupy a very large 
volume relative to their molecular weight and are responsible for cartilage 
resilience and elasticity (Hardingham et al. , 1991). 
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The proteoglycans are structured around a linear polypeptide core and 
carbohydrate chains are linked to the core, which radiate outward like bottlebrush 
bristles. The carbohydrates are mostly in the form of glycosaminoglycan 
molecules (GAGs) that are sulphated and carry an overall strong negative charge. 
The consistency of the cartilage matrix relies on electrostatic bonds between the 
GAG side chains and other matrix components as well as the binding of water to 
GAG. 
Chondroitin sulphate, keratan sulphate and hyaluronic acid are all GAGs found in 
articular cartilage. Hyaluronan is an unsulphated GAG that makes up 1-10% of 
the cartilage and is widely distributed in most of the tissues and body fluids in 
mammalian species as well as in microorganisms (Roughley and Lee, 1994). 
Aggrecan, the most abundant proteoglycan in articular cartilage (Billington eta/., 
1998), is a macromolecule that contains aggregated GAGs attached to the protein 
core and represents up to 10% of dry weight of cartilage (Bolton et a!., 1999). 
After synthesis of protein core, up to 100 chondroitin sulphate chains and 50 
keratan sulphate chains are added during post-translational processing and these 
carbohydrates make more than 90% of the molecular mass. The protein core 
consists ofthree globular (Gl , G2 and G3) and two extended domains. G1 and G2 
are at the N-terminus and G3 at the C-terminus of the core protein (Hardingham 
and Fosang, 1995) (see Fig. : 1.4.3.3). The extended domains form specialised 
attachment regions and a site for aggregation with hyaluronan. 
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Fig 1.4.3.3: The structure of aggrecan 
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Fig.1.4.3.3: Structure of aggrecan adapted from: Hardingham T.E. and Fosang 
A.J. (1995) The structure of aggrecan and its turnover in cartilage. JRheumatol. ; 
21 (1); 86-90. 
Aggrecan has the ability to interact with hyaluronic acid to form large 
proteoglycan aggregates that provides the cartilage with its osmotic properties, 
which enables the cartilage to resist compressive loads. Many non-aggregating 
proteoglycans of articular cartilage include decorin, biglycan, and fibromodulin 
and are characterised by their ability to interact with collagen. 
Decorin is able to interact with both the type II collagen fibrils of hyaline cartilage 
and the type I collagen fibrils of other connective tissues. In vitro studies have 
shown that the presence of decorin influences both the rate of collagen 
fibrillogenesis and the fibril diameter (Keene et al. , 2000). 
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The precise function of biglycan that is localized within the pericellular matrix of 
connective tissue cells is unknown, however it is speculated that it may participate 
in the collagen network assembly. The precise function of fibromodulin is also 
unknown, but it is speculated that it could restrict the function of decorin by 
limiting the interaction between collagen fibromodulin fibrills (Roughley and Lee, 
1994). 
1.5: Arthritic joint pathology 
The synovial membrane surrounds the moveable joints of the skeleton and is the 
centre of abnormality in pathological conditions. At its later stages it may involve 
other organs, such as the skin, lungs, nerves, blood vessels and heart . With the 
passage of time, the inflamed membrane increases in thickness to form pannus 
tissue (see Fig. 1.5). 
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Fig.l.S: Diagram of an arthritic cartilage joint 
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Adapted from: Roitt. l .. Brostoft: J. & Male, D. ( 19%) /mmunology(J'~ec{) ; Mosby, USA 
Fig. 1.5: Diagram illustrating an arthritic joint, which is undergoing some 
characteristic changes, observed in rheumatoid arthritis. Picture adapted from, 
Roitt, 1. , Brostoff, J. and Male D. (1996) Immunology (41h ed.) ; Mosby, USA. 
The interface between pannus and cartilage is occupied pre-dominantly by 
activated macrophage populations and synoviocytes, which through numerous 
signalling pathways, interact with each other and eventually result in the 
progression of cartilage and bone destruction (Bresnihan, 1997). The inflamed 
synovium is rich in T cells, plasma cells and macrophages (Chang et al., 1997). 
Studies indicate that T -cells play an important role in the initiation and 
maintenance of RA (Tayler et al. , 1994). In addition, the pannus tissue also 
contains hypermeable angiogenic vessels, that cause edema, joint inflammation 
and pain, thereby promoting the continued influx of inflammatory cells resulting 
in production and release of angiogenic factors within the joint. These combined 
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effects result in joint inflammation, mvas10n of bone and cartilage, leading to 
ligament damage and deformity . 
1.5.1: Inflammation 
Inflammation is a physiological response to tissue damage or injury characterised 
by redness, heat, swelling, pain and reduced function . Synovial lymphocytes 
release lymphokines that activate macrophages and other cells to participate in 
destruction and removal of foreign invaders. In addition, many substances 
activated during the inflammatory process repair the injury and destroy activated 
cells, causing inflammation to eventually subside. Inflammation, depending on 
duration, can be classified as either acute (short-term), or chronic (persistent). 
In acute inflammation, changes in small blood vessels result in fluid and 
granulocytic cells accumulation at the site of injury. This reaction triggers a range 
of systemic responses such as fever, leukocytosis, protein catabolism and hepatic 
synthesis of plasma proteins such as C-reactive protein until the inflammation 
declines. Acute inflammation may or may not lead to chronic inflammation, 
which is characterised by tissue infiltration by macrophages and lymphocytes. 
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1.5.1.1: Inflammation and angiogenesis 
Inflammation can promote angiogenesis (Fava et a/. , 1999), i.e. growth of new 
capillary blood vessels from pre-existing vasculature (Risau, 1997), which may 
enhance tissue inflammation (Walsh and Pearson, 2001). Angiogenesis and 
endothelial cells contribute to the proliferation of inflammatory synovial tissue, 
the production of proteolytic enzymes, and eventually invasion and destruction of 
joint surfaces. Inhibition of chronic inflammation may be expected to inhibit 
angiogenesi s where the stimulus for vascular growth is derived from 
inflammatory cells (Storgard, 1999). 
Inflammation and angiogenesis can develop independently, but their co-existence 
may lead to more severe and persistent inflammation (Risau, 1997). Angiogenesis 
may also occur in the absence of inflammation, e.g. female reproductive cycle and 
during embryonic growth. 
Inflammatory cells, such as monocytes and macrophages, contain and release a 
variety of angiogenic growth factors including: basic fibroblast growth factor 
(bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), Tumor necrosis factor alpha (TNF-a). The PDGF has been 
detected in synovial fluids of rheumatoid patients (Takeuchi et al., 1994) and is 
thought to play a crucial role in cartilage repair by initially causing cartilage 
degradation followed by promoting new matrix synthesis (Harvey et al., 1993). 
Insulin-like growth factor (IGF-1) and basic fibroblast growth factor (b-FGF) are 
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also present in OA cartilage and are likely to contribute to reparative attempts 
(Lotz et al., 1995) 
The cellular accumulation is also accompanied by the release of inflammatory 
mediators such as prostaglandins (PGs), cytokines, matrix metalloproteinases 
(MMPs), chemokines and Reactive Oxygen Species (ROS) (Lydyard and 
Edwards, 1994). 
1.5.1.2: Prostaglandins and inflammation 
Prostaglandins PGs are derivatives of fatty acids, and belong to a subclass of 
lipids known as the eicosanoids, because oftheir structural similarities to the C-20 
polyunsaturated fatty acids, the eicosaenoic acids. PGs, thromboxanes and 
leukotrienes are all classified as members of eicosanoid class (Benjamini , 1996). 
Prostaglandin E2 (PGE2) is one of the most important prostanoid that causes 
cartilage degradation and bone resorption. The ability of various pro-
inflammatory agents, e.g. Interleukin-1 (IL-l), TNF, thrombin, complement 
components and Tumor growth factor- beta (TGF-P) to stimulate bone resorption 
may be mediated in part, at least by increased PG synthesis. In many cases it may 
occur due to the induction of cyclo-oxygenase-2 (COX-2) in response to 
inflammatory stimuli (Hukkanen et al., 1998). Inflammation can be controlled by 
reducing or inhibiting the formation of these compounds (Mike, 1997). 
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1.5.1.3: Cytokines and inflammation 
Cytokines are essential signalling molecules in inflammation and that mediate 
potent stimulatory or inhibitory biological effects on most cell types. Cytokines 
also function as mediators of pathology in infectious, inflammatory and immune 
diseases, including mediation of both acute and chronic inflammation associated 
with connective tissue destruction. In inflammatory conditions, a dramatic 
increase in cytokine production can be seen as the equilibrium between the 
cytokine production and its control is disturbed (Miller et al. , 1 993). 
1.5.1.3.1:Interleukin-1 (IL-l) and inflammation 
IL- l , a pro-inflammatory cytokine produced by several cell types including 
endothelial cells, synoviocytes and chondrocytes, has been shown to result in 
widespread matrix degradation, including loss of proteoglycans and collagens. 
There are 3 members of IL-l family, IL-la, IL-l (3 and IL-l receptor antagonist 
(IL-1Ra). IL-la is not commonly found in circulation, except following cell 
death, whereas IL-l (3 and IL-lRa exert their activity external to the cells. 
IL-l receptors have two forms, IL-lR type I (IL-lRl) and IL-lR type II (IL-lRII). 
IL- lRI has been shown to transduce signals. Whereas, the type II receptor is 
thought to be incapable of transducing signals to cells because of its short 
intracellular domain. IL-lRl requires binding of IL-l , an accessory protein and 
GTPase to produce an intracellular protein kinase cascade, whereas the IL-lRll 
will bind IL-1(3 and reduce cellular activity. The soluble form of IL- lR type 1, 
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however, does not have the necessary binding site for the receptor accessory 
protein and will not produce a response (Tayler et al. , 1994). The surface 
expression of IL-lRl receptors can be modulated depending on cell type and 
regulating factor. It has been shown that IL-l down regulates the expression in T 
cells, whereas it up regulates expression via prostaglandins in other cell types 
including fibroblasts and macrophages. 
Furthermore, an important role of IL-l p in arthritis is supported by the occurrence 
of spontaneous arthritis in IL-lRa knockout mice and elicitation of full-blown 
arthritis in TNF-deficient mice (Dinarello et al. , 1998). 
1.5.1.3.2:Tumor necrosis factor (TNF) and inflammation 
IL-l P and TNF-a are found in increased amounts in synovial fluids of affected 
joints, and in the circulation of RA patients (Arend and Dayer, 1990). TNF exists 
in two forms, TNF-a and TNF-13, which have similar properties to each other and 
IL-lf3 (Van den Berg et al., 1999) including induction of PGs, MMP synthesis, 
the stimulation ofbone and cartilage resorption and mitogenesis . 
The pro-inflammatory effects of TNF-a are amplified by its potential to act as a 
potent paracrine molecule, by inducing other pro-inflammatory molecules such as 
IL-lP, (Granulocyte-macrophage colony stimulating factor) GM-CSF and nitric 
oxide (NO) (Brennan et al. , 1992). 
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1.5.1.3.3: Interaction of IL-lB and TNF-a with other cytokines in 
inflammation 
IL-l~ is not a dominant cytokine in early joint swelling, but plays a pivotal role in 
sustained cell infiltration and erosive cartilage damages (Van den Berg et a!. , 
1999). On a molar basis IL- lP is more potent than TNF-a , but both can act in a 
synergistic fashion (Hukkanen et at. , 1998). 
Both IL-l~ and TNF-a are crucial in initiating the next series of reactions in an 
inflammatory response and this can induce aggrecanase-mediated aggrecan 
catabolism and stimulate the production of IL-6 by articular chondrocytes. IL-l~ 
share significant primary amino acid sequences and a 12~ sheet common structure 
with the IL-18, a crucial upstream cytokine that, with IL-12, induces IL-l~ and 
TNF, and promotes T cell differentiation. T helper 1 (Thi) cells may aggravate 
arthritis and joint destruction through the production of ll.,-17 which shows joint 
destructive potential independent ofiL-1~ (Dinarello et al., 1998). 
Little et al., (1999) demonstrated that at the reactive site, IL-lP and TNF-a act on 
stromal cells, including fibroblasts and endothelial cells, to cause the release of 
secondary wave of cytokines. This secondary wave of cytokines amplifies the 
homeostatic signal and initiates the cellular and cytokine cascades that are 
involved in complicated process of Acute Phase Reaction (APR) (Guerne, 1990). 
APR, is a dynamic homeostatic process that involves all major systems of body 
that normally lasts only for a few days. However, in case of chronic and recurrent 
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inflammation, an aberrant continuation of some aspects of APR may lead to tissue 
damage and other complications. During APR higher levels of plasma proteins 
are required, which are mostly synthesized by hepatocytes . Some of these factors 
however, are produced by other cell types, such as monocytes, adipocytes, 
endothelial cells and fibroblasts . 
Release of IL-l f3 and TNF -a by synovial macro phages stimulates release of 
collagenase, elastase, plasminogen activator and prostaglandins, which play a vital 
role in tissue matrix destruction. 
1.5.1.4: Cytokines and matrix degradation 
It is now generally accepted that cytokines play a pivotal role in inflammatory 
joint diseases, especially with regard to tissue destruction and remodelling. ll.,-10 
plays a dual role in cartilage matrix degeneration by promoting extracellular 
proteinase action such as MMPs (increased degradation) and by suppressing the 
synthesis of extracellular matrix molecules (inhibition of repair) (Harvey et a/. , 
1993). Furthermore, IL-10 suppresses the synthesis of type IT collagen and 
proteoglycans, and inhibits TGF-[3-stimulated chondrocytes proliferation. TGF-B 
is a potent chondrocyte growth factor that not only stimulates de novo matrix 
synthesis, but also counteracts cartilage degradation by down regulating IL-l 
receptor expression and by increasing TL- lRa release and Tissue 
Metalloproteinase Inhibitor (TIMP) expression. 
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Both a and f3 forms ofiL-1 have been revealed to cause matrix degradation in RA 
and OA (Mike, 1997). IL-1(3 interacts with chondrocytes through a cell surface 
receptor, stimulating chondrocytes and synovial cells to secrete proteinases that 
are categorised into four classes; serine/threonine proteinase, cysteine proteinases. 
aspartic proteinases and MMPs. Members of each of the four classes of 
proteinases have been implicated in the deterioration of cartilage but the early 
steps in cartilage breakdown involve the activity ofMMPs. 
IL-l f3 can induce the production and expression of MMPs in chondrocytes, while 
decreasing the production of TIMPs (Lawrence et al., 1997). Recent studies by 
Sasaki et al., (1998) reported that IL-l f3 stimulated the production of MMP-3 and 
MMP-9 in cultured rabbit articular chondrocytes. 
1.6: Matrix Metalloproteinase family 
.MMP is a large family ofhighly conserved zinc dependent endopeptidases that 
include MMPs (see section 1.6.2) and the ADAMTS (see section 1.6.1) (A 
Disintegrin and Metalloproteinase domain, with Thrombospondin motifs) . 
.MMPs and ADAMTS play important roles in a variety of normal and 
pathological conditions including RA (Cal eta/. , 2002). 
1.6.1: ADAMTS 
ADAMTS are a novel family of extracellular proteinases and are the members of 
transmembrane glycoproteins (Huovila eta/. , 1996) found in both mammals and 
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invertebrates. They perform wide range of activities including proteolysis and cell 
to cell adhesion within extracellular matrix (Nagase et al. , 1999). 
Structure of ADAMTS 
ADAMTS have a characteristic conserved domain structure. A N-terminal single 
sequence is followed by a pro-domain, a metalloproteinase domain, a disintegrin 
domain and a cysteine rich region. Most of the members also have a 
transmembrane domain followed by a cytoplasmic tail at the C-terminus. 
Fig.1.6.1: Domain Structure of ADAMTs protein 
N-tenninus 
Pro Metalloproteinase Dislnt Cys-rich EGF TM Cytoso li c 
domain 
in us 
Fig. 1.6.1: A characteristic domain structure of an ADAMT protein, drawn using 
Microsoft Power Point 1997. 
The common domains in ADAM proteins are: pro-metalloproteinase, disintegrin-
like (Dislnt) and cysteine-rich (Cys-rich). The majority of ADAMTS are type-I 
integral membrane proteins, containing EGF-like, transmembrane and cytosolic 
domains. ADAMTS proteins are secreted, containing spacer and unique regions 
as well as one or more copies of the thrombospondin type I (TS) motifs (Tang, 
2001). 
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Members of ADAMTS famil y have been implicated in diverse processes from 
cellular adhesion and proteolytic processing of important cell surface molecules to 
embryonic development and angiogenesis. 
Functions of ADAMTS 
Most of the ADAMTS genes are expressed at low levels in adult tissues. 
ADAMTS-1 , 4 and 7 are found to be more abundant, by both Northern analysis 
and Transcription Polymerase Chain Reaction (RT-PCR) studies of transcript 
levels in different tissues (Kuno el al , 1997). ADAMTS 2, 3 and 8 are generally 
lower in abundance and are detected at low levels in particular tissues whereas, 
ADAMTS-5 and 6 are exclusively expressed in placenta (Hurskainen et a/., 
1999). 
ADAMTS-1 plays a role in inflammation, angiogenesis and organ morphogenesis 
(Blobel et al., 1992) and ADAMTS-2 has a role in pro-collagen processing. 
Whereas, ADAMTS 6, 7 and 8 are involved in angiogenesis. ADAMTS-4 and 5 
are implicated in aggrecanase-mediated deterioration of cartilage aggrecan in 
arthritic disease. 
1.6.2: Matrix-metalloproteinases ( MMPs) 
MMPs is a family of multiple genes that is classified into sub-families based on 
their domain structures and substrate specificities. Sub-families include 
collagenases, gelatinases, stromelysins, and membrane type MMPs (MT -MMPs) 
that are involved in breakdown and turnover of extracellular matrix. 
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Collagenases (MMP-1 ,8 and 13 ), the most specific enzymes, are alone able to 
degrade cartilage native collagen fibrils and exhibit high specificity for their 
substrates. MMP-13 cleaves collagen-1 , the predominant collagen constituent of 
the cartilage and the cleavage products of collagen fibrils provide excellent 
substrates for gelatinases (MMP-2 and - 9) . 
The gelatinases degrade denatured collagen (gelatin) and the collagen present in 
the basement membrane, type IV collagen. Stromelysins, due to their broad 
substrate specificity, degrade many of the extracellular proteins (Nagase and 
Woessner 1999) including gelatins, proteoglycans fibronectin and type IX 
collagen. 
Among six different MT-MMPs (MT1-MMP to MT6-MMP), all except MT4-
MMP and MT6-MMP can activate pro-MMP-2 (Okada, 2000). Ohuchi et a/. , 
(1997) demonstrated that MTl-MMP, an extracellular matrix degrading enzyme 
shares substrate specificity with interstitial collagenase (collagenase 1) and is 
capable of digesting type I, (guinea pig), U (bovine) III (human) collagens as well 
as other extracellular matrix components, including fibronectin, lamin, aggrecan 
and gelatin . 
Activation of rheumatoid synovial cells by IL-1P causes the induction of MTI -
MMP expression, which promotes matrix degradation by activating pro-MMP-2 . 
This suggests a mechanism whereby cytokines may contribute to cartilage 
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destruction in RA (Honda et a/. , 2000). Increased expression of MT 1-MMP and 
MT3-MMP mRNA have been detected in RA synovium (Pap et al. , 2000). 
Control of MMP synthesis, activation and activity is tightly regulated under 
physiological conditions, systematically degrading bone cartilage collagen and 
proteoglycans (Park and Mecham, 1998). Thus, the accelerated turnover of 
collagen associated with joint diseases may result from a number of factors , 
including increased synthesis and activation of MMPs and /or an imbalance in 
levels ofMMPs and their inhibitors. 
A recent study by Hirai et a/. , (200 I) demonstrated that MMP production by 
rheumatoid synovial cells is modulated by NO, which contributes to degradation 
of extracellular matrix components in RA. 
1. 7: Nitric oxide and cartilage degradation 
NO, a potential vasodilator, is synthesized from L-argininine by the action of 
nitric oxide synthase (NOS), which exists in three isoforms: an endothelial 
isoform (eNOS), a neuronal isoform (nNOS) and an inducible isoform (iNOS). 
eNOS has been identified in endothelial cells, endocardial cells, platelets, 
epithelial cells and certain white cells, whereas, nNOS is located primarily in 
neurons but it is also expressed in skeletal muscle. iNOS was first cloned from 
murine macrophages and subsequently from human hepatocytes and chondrocytes 
(Cho et al., 1992; Charles et al. , 1993; Geller et al. , 1993). Human iNOS shares 
50-60% homology with human eNOS and 80% with murine iNOS . 
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Exposure to pro-inflammatory stimulus induces iNOS production in a variety of 
cells including chondrocytes, synoviocytes, macrophages, smooth muscle and 
endothelial cells, cardiac monocytes and hepatocytes, osteoblasts and osteoclast 
like cells (Brandi el a/., 1995; Hukkanen et at., 1995). 
Stadler et al. , (1991) first implicated NO in joint inflammation by demonstrating 
that the cytokine IL-l~ induced NO production in cultures of rabbit chondrocytes, 
as did lipopolysaccharide (LPS). This is supported by more recent in vivo work 
(McCartney-Francis el a/. 1993); Stefanovic- Racic et a/. 1994b) in which non-
specific inhibitors of NO synthesis substantially suppressed development of joint 
inflammation in chronic models of arthritis. The elevated levels of NO in both the 
serum and synovial fluid of rheumatoid patients (Farell et a/., 1996) as compared 
with normal controls suggests a pro-inflammatory role for NO in RA. 
1. 7.1: Nitric Oxide and cartilage matrix turnover 
NO induces MMP-2 production by rheumatoid synovial cells and may regulate 
chondrocyte-mediated cartilage extracellular matrix remodelling. Initial studies to 
identify a role for endogenously produced NO in cartilage metabolism, therefore 
focussed on matrix turnover (Hukkanen eta/., 1998). 
Ghael (1997) administered nitric oxide donor, S-nitroso-N-acetyl-D, L-
penicillamine (SNAP) under conditions that are close to those found in vivo, and 
demonstrated that NO induced degradation of heparin and heparin sulphate. It has 
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been suggested that peroxynitrite, a breakdown product ofNO, partially degrades 
Chondroitin sulphate A, Chondroitin sulphate B and Chondroitin sulphate C, the 
constituents of the basement membranes of many tissues (Hassan eta/. , 1998). 
Moreover, eNOS has been shown to inhibit the synthesis of proteoglycans by 
articular chondrocytes. The only exception is bovine articular cartilage, which for 
an unknown reason lacks this response (Stefanovic- Racic et a/. , 1996b ). In all 
other species that have been investigated, including rabbits, mice and humans it 
strongly suppresses the incorporation of sulphate (S04-2) into cartilage 
proteoglycans (Hauselmann et al., 1994). The mechanism through which NO 
inhibits proteoglycan synthesis is unknown, but the preceding data suggests an 
effect on the synthesis of core protein rather than on the synthesis of GAGs 
(Stefanovic - Racic et al., 1997). 
1. 7.2: Nitric Oxide and angiogenesis 
Sasaki et al., (1998) reported that IL-l-stimulated elevation ofNO level via iNOS 
mRN A expression mediates gene expression and production of MMPs and b-
FGF. Furthermore, it was suggested that molecular mechanisms implicated m 
articular cartilage degradation are followed by angiogenesis in the synovium of 
arthritic joints. 
Tamura et al., (1996) demonstrated that ll..,-1-stimulated NO production by rabbit 
articular chondrocytes co-cultured with bovine aortic endothelial cells, caused 
MMP-mediated extracellular matrix degradation. This released large amounts of 
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b-FGF stored in the matrix and stimulated production of adjacent bovine aort ic 
endothelial cells proliferation . Extended exposure of umbilical vein endothelial 
cells (HUVEC) to human recombinant erythropoietin (rHuEPO), has been shown 
to induce NOS activity (Benerjee et al., 2000). Therefore, NO produced from 
rabbit articular chondrocytes following ~-1 treatment may modulate angiogenesis 
in the synovium of arthritic patients. 
1.7.3: Nitric oxide (NO) and apoptosis 
Conrozier et al. , (1998) reported that the increased production of NO in rabbit 
articular cartilage following stimulation with ~- 1 induces apoptosis in 50% of 
articular chondrocytes compared to 10% in normal cartilage. Apoptosis in several 
types of cells such as lymphocytes, granulocytes, hematopoietic cells, 
chondrocytes, and keratinocytes play a role in both normal and pathological 
conditions (Conrozier et al. , 1998). 
Yatsugi et al., (2000) in a study, on human cartilage suggested that the degree of 
apoptosis in chondrocytes is closely related to cartilage destruction and that 
chondrocytes in RA more readily undergo apoptosis than those in OA. However, 
apoptosis participates in maintaining equilibrium between processes of cell 
proliferation, such as myelopoiesis, erythropoiesis, and thrombopoiesis . 
Erythropoiesis is the formation of red blood cells in hematopoietic tissue, such as 
the bone marrow or spleen and is regulated by EPO (Jelkmann, 1996). 
41 
1.8: Erythropoietin (EPO) 
EPO is a multifunctional trophic factor that has different sites of expression, a 
tissue-specific regulation and several mechanisms of action. It is primarily 
produced by the cells of peritubular capillary endothelium of kidney. However, 
secondary amounts of this hormone are synthesized in liver hepatocytes of healthy 
adults (Tabbara, 1993). Recent studies by Chikuma et a/. , (2000) identified 
another two sites of EPO production the uterus and the brain, in which the 
expression of EPO appeared to be regulated in a tissue-specific manner. In the 
brain, there is a paracrine EPO/EPO receptor (EPOR) system that is independent 
of the endocrine system in erythropoiesis and prevents neuron death 
(Digicaylioglu et a/. , 1995) and EPO in the uterus induces estrogen (E2)-
dependent uterine angiogenesis (Yoshiko eta/. , 1998). 
Existence ofEPO was proven by the end of 19111 century based on the di scovery 
that hypoxia increases the production of red blood cells. EPO was identified as a 
serum factor in the 1950's, and in 1977 Miyake and co-workers succeeded in 
purifying it by using the urine of patients with aplastic anaemia as a starting 
material (Yoshimura et al., 1 996). The human EPO gene was cloned in 1985 
using a partial amino acid sequence from this purified EPO and is currently 
employed to treat anaemia associated with various complications. (Yoshimura et 
al. , 1996). 
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1.8.1: Clinical role of EPO 
Human Recombinant EPO (rHuEPO) is effectively administered to treat anaemia 
in various chronic complications including Anaemia of Chronic disease (ACD) 
that is a common feature of active RA (Jelkmann et a/. , 1996). Pathogenesis of 
ACD is characterised by decreased serum iron, decreased total iron-binding 
capacity and increased iron reserves that occur in a variety of diseases including 
cancer, chronic infections and RA. The most controversial and stimulating aspect 
of the pathogenesis of ACD in autoimmune disorders is the role of iron 
metabolism and NO, which contributes to the regulation of Iron cellular 
metabolism. 
Inflammatory agents such as, TNF-a, IL-lf3 and IL-6 are thought to contribute to 
the pathogenesis of anaemia, possibly by inhibiting EPO production (Faquin et 
a!., 1992). Akimoto eta!. , (1999) reported the inhibition of IL-lf3-induced NO 
production in rat vascular smooth muscle cells by EPO, via suppression of iNOS 
mRNA and protein by EPOR, through an unknown mechanism. 
In a study performed be Carlini et a!. , (1995), it has been reported that rHuEPO 
stimulates angiogenesis in vitro. However, the mechanism by which rHuEPO 
induces angiogenesis, a well-known feature of arthritic synovJUm is not 
understood. However, it has been hypothesised that it may be related to the 
rHuEPO-stimulated enhancement in the cell proliferation and migration of 
endothelial cells (Anagnostou et al., 1990). 
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1.8.2: Mechanism of action of EPO 
Although EPO has different sites of activation and several mechanisms of action 
depending on the tissue type, the oxygen tension or hypoxia is the principal 
stimulus of EPO production. Hypoxia induces the expression of EPO gene via 
binding of hypoxia-inducing factor to the hypoxia-inducible enhancer located on 
the EPO gene, in the 3' flanking region . Additional factors, such as hepatic nuclear 
factor 4, may bind to the EPO gene promoter, which acts synergistically with the 
enhancer to promote transcription of the EPO gene under conditions of hypoxia 
(Wang et al., 1996). 
EPO receptors found on erythroid cells, primarily on colony forming unit 
erythrocytes (CFU-E) (about 1000 receptors per cell) are considered to be the 
primary target for EPO bindi ng (Wu et a/., 1995). The signal for cellular 
proliferation and differentiation into erythroblasts is thought to originate at the 
EPOR. The cytoplasmic domain ofEPOR can be divided into two major regions. 
The proximal half of the cytoplasmic domain, is needed for generating the signals 
for proliferation and differentiation such as the induction of globin synthesis 
whereas, the distal C-terminus is not required for signalling but acts to inhibit the 
signals. 
1.9: Aim of the investigation 
lt has been widely accepted that administration of rHuEPO is beneficial for 
anaemia of RA patients. However, a major side effect of this treatment is the 
development of clinically significant hypertension (Bode-Boger e/ a/., 1992). 
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Nevertheless, the effect of EPO on cartilage metabolism has not yet been 
elucidated. 
The aim of the current research project was to investigate the effect of EPO on 
three model systems, a Swiss 3T3 model of rheumatoid synovial fibroblasts an in 
vitro model of porcine nasal cartilage degradation and in porcine nasal cartilage 
system co-cultured with fibroblast monolayer. The co-culture system would be 
established to study both the effect of fibroblast-mediated cartilage breakdown 
and chondrocyte-mediated cartilage resorption, following treatment with 
cytokines. 
Chondrocytes are not the only source of NO in human arthritic joints, 
macrophages and synovial fibroblasts have also been shown to produce high 
levels of NO via iNOS activation (Farell and Blake 1 996). In arthritic joint, the 
loss of cartilage may be due to increased degradation and/or decreased synthesis. 
Thus, NO would be measured as a marker of inflammation, that may promote the 
loss of GAG from the matrix, GAGs content of cartilage and levels of GAGs 
release would be ascertained to determine the effect on m+atrix remodelling, in 
response to cytokine treatments. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.0: Introduction 
The primary aim of this investigation was to develop an in vitro cell model of 
rheumatoid synovial fibroblasts using Swiss 3T3 fibroblast monolayer. An in 'itro 
model of chondrocyte-mediated cartilage resorption was established using porcine 
nasal cartilage explants. The porcine cartilage explants were integrated with Swiss 
3T3 fibroblast monolayer to provide a more representative model of the inflamed 
joint by mimicking a pannus/cartilage interface. 
Swiss 3T3 murine fibroblasts were a generous gift provided by the University of 
Hertfordshire. Swiss 3T3 fibroblast monolayer was established using cell culture 
techniques (2.2.1). Cell culture media for explant and fibroblast cell culture was 
prepared (2.1 ), using standard aseptic techniques (2.1.1). 
Porcine nasal samples were obtained from Evans and Sons abattoir, in Sheldon 
Bedford. The cartilage was extracted and challenged with varying treatments 
following 24 hours incubation in complete supplemented medium (CSM) (section 
2.2.2.3). 
The two systems were then integrated to develop a co-culture system (2.2.3). The 
effects of pro-inflammatory cytokines such as IL- l~ rHuEPO were tested for their 
effects on NO production (2.4) and tissue remodelling via GAG assay (2 .5) . 
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2. 1 : Preparation of cell culture components 
Cell culture media for explant and fibroblast cell culture was prepared, usmg 
standard aseptic techniques (2.1 .1 ). 
2.1.1: Aseptic techniques 
Cell culture components were prepared inside class II hood that was cleaned with 
70% IMS before and after use. The hood was switched on 5 minutes prior to 
cleaning, then left for 1 0 minutes prior to use and 5 minutes prior to switching off. 
Separate hoods were maintained for primary and secondary cell culture to reduce 
the cross contamination potential and were cleaned at monthly intervals with 1% 
wlv Virkon solution then 70 % industrial methylated spirit (IMS) Water tra s 
inside the incubators were cleaned with 1% virkon, then 70% rMS at weekly 
intervals before changing the autoclaved distilled water. 
2.1.2: Complete supplemented medium (CSM) 
CSM was prepared using Dulbecco's Modified Eagles Medium (DMEM) (Sigma 
05921) (1 000 mg glucose I phenol free) , heat inactivated foetal calf serum (FCS) 
(Sigma F9665) (10% by volume), lOmM L-glutamine (Sigma G7513), 100 Ulml 
Penicillin I 100 ~g/ml Streptomycin solution (pen.strep .) (Sigma P4333). 
2.1.3: Dulbecco's Modified Eagles Media (DMEM) 
DMEM was purchased in 500ml bottles and kept at 4°C until required for use. 
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2.1.4: Heat inactivated foetal calf serum (FCS) 
FCS was purchased in lOOm\ bottles and defrosted at room temperature. lt was 
then prepared in 25m! aliquots in 30m! sterile plastic universals and aliquots were 
refrozen at - 20°C until required for use. 
2.1.5: L-Giutamine 200mM solution 
L-Glutamine was purchased in lOOm! bottles, thawed at room temperature and 
then prepared in 5ml aliquots in 30ml sterile plastic universals. The aliquots were 
frozen at -20°C until required for use. 
2.1.6: Penicillin (10,000 U/mg) /Streptomycin (lOmg/ml) (penstrep.) solution 
Pen.strep. solution was purchased in lOOm! stock bottles, defrosted at room 
temperature and then prepared in lOrn! aliquots in 30m! sterile plastic universals. 
The aliquots were refrozen at - 20°C until required for use. 
2.1. 7: Preparation of cytokines for use in cell I tissue culture experiments 
Cytokines such as IL-1 ~ (200-0lB), TNF-a (C 67320) and LPS (endotoxin 
derived from E. Coli 055 : B5) (LPS) were purchased from Peprotech EC and then 
reconstituted in DMEM at a concentration of 500ng/ml. EPO (Sigma E5627), was 
reconstituted in DMEM at a concentration of 0.5U/ml. The reconstituted 
cytokines were stored in sterile cryopreservation vials at -20°C until required for 
use. 
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2.2: Preparation of RA models 
The Swiss 3T3 model ofrheumatoid synovial fibroblasts , porcine nasal cartilage 
explant model and a co-culture model were prepared as follows: -see section 
2.2.1, 2.2.2 and 2.2.3 respectively . 
2.2.1: Swiss 3T3 fibroblast cell culture 
Fibroblasts were resuscitated (section 2.2.1.2) from cryopreservation (section 
2.2.1.1) and were prepared to 80% confluent monolayers, which were then used 
for either experiment alone (section 2.2.1.3) or in co-culture with porcine nasal 
cartilage explants (section 2.2.3). 
2.2.1.1: Cryopreservation of fibroblasts 
The 90% confluent fibroblast monolayer in 25m] tissue culture flasks was washed 
with HBSS, then trypsinized using an initial volume of Sml 0.25 % trypsin-
EDT A Fibroblasts were suspended in 1Om I of CSM I trypsin and were 
centrifuged at 600rpm for 6 minutes to obtain a cell pellet. This was resuspended 
in 1 ml of cryopreservation medium, containing 90% FCS and 10% Dimethyl 
sulfoxide (DMSO) (Sigma D2650). The supernatant CSM I trypsin was decanted 
off and cells were cooled at a rate of 1 °C I hour in a controlled rate freezer unit 
then stored in cryopreservation tubes in liquid nitrogen until required for further 
use. 
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2.2.1.2: Resuscitation of fibroblasts 
Fibroblasts were resuscitated, by adding cells I DMSO to 1Om! of 10% CSM to 
dilute DMSO and therefore reduce its toxicity. Following centrifugation at 600 
rpm for 6 minutes, a cell pellet was obtained to which 10% CSM was added and 
the supernatant decanted. Cells were added to 25m! tissue culture flasks and 
incubated at 37°C for the initial passage following cryopreservation. CSM was 
changed regularly every 48 hours in stock flasks of fibroblasts . 
2.2.1.3: Fibroblast experiments 
Fibroblasts were seeded at a concentration of l x 105 cellslml in 25 m! tissue 
culture flasks and grown to 90% confluence in 1Om! of 10% CSM inside a 
secondary incubator. CSM was refreshed in stock flasks of fibroblasts at every 48 
hours until 90% confluent monolayers were prepared. CSM was removed and 
fibroblasts were washed with 5ml of HBSS and were trypsinized using an initial 
volume of 2.5ml 0.25 %trypsin-EDT A The adherent fibroblasts were observed 
using a phase contrast microscope until they had adopted a rounded morphology 
(approximately 30 seconds). Following the removal of 2ml of trypsin-EDTA, 
fibroblasts were incubated for 2 minutes and the tissue culture flasks were gently 
tapped to facilitate fibroblasts detachment from the plastic. Trypsin activity was 
inhibited by adding 9ml of CSM to flasks and the fibroblasts were suspended in 
10 ml of CSM I trypsin, then centrifuged at 600 rpm for 6 minutes to obtain a cell 
pellet. The supernatant containing CSM I trypsin was decanted off and the cells 
were resuspended in 2m! ofHBSS. 
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Fibroblasts were seeded in 24 well tissue culture plates at a density of 1 x 104 cell s 
per ml of CSM and grown to 80% confluent monolayer. Confluent fibroblast 
monolayers were challenged with varying concentrations of EPO alone or in 
combination with ll..,-1 ~ in a series of time course studies over 3 days. Culture 
media and treatments were replenished every 24 hours and supernatant samples 
were collected into micro centrifuge tubes and frozen at -20°C until required fo r 
the measurement of nitrite production (section 2.4). Cell density and viability was 
determined using trypan blue exclusion assay (section 2.3). 
2.2.2: Porcine cartilage explant culture 
Porcine cartilage was isolated (section 2 .2.2.1), washed (section 2 .2 .2 .2) and then 
used for either individual or co-culture experiments with 3T3 fibroblast 
monolayer (section 2 .2 .3). 
2.2.2.1: Isolation of porcine nasal cartilage 
Porcine noses were sprayed with 70% ethanol and a vertical incision was made in 
the upper region of the nose to remove unwanted tissue using scalpel blades and 
the cartilage was extracted. A cork borer was used to bore through the cartilage to 
produce 3-4 mm round discs, and each disc was further divided into two sections, 
which were HBSS (Sigma H8264) supplemented with antibiotics ( 1 OOU/ml 
penicillin, lO~g/ml streptomycin, pen.strep) (Sigma P4333) solution prior to 
washing. 
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2.2.2.2: Washing procedure for cartilage 
In order to reduce the risk of infection a wash solution was prepared b 
supplementing HBSS with antibiotics. Following the removal of connective 
ligament tissue, discs were transferred into a 25m! sterile universal and washed 
by shaking vigorously. This process was repeated 5 times to reduce the risk of 
infection, and the debris was decanted off with the supernatant. Following 
weighing, the discs were transferred into 24 well tissue culture plates, inside the 
class II sterile hood and were cultured in humidified 5% carbon dioxide (C02) I 
95% air incubator at 37°C. 
2.2.2.3: Cartilage explant experiments 
After weighing, the cartilage discs were cultured in 1 ml of CSM for 24 hours 
before the addition of treatments to explants. Cartilage media was refreshed every 
24 hours until 3 days. For the initial experiments, the cartilage discs were washed 
with Tml of HBSS, following collection in the eppendorfs and were digested 
(section 2.2.2.4) for analysis of their GAG content. However, in the later 
experiments cartilage discs were disposed of and the media supernatant samples, 
collected in micro centrifuge tubes, were frozen at - 20°C until required for the 
measurement of GAGs loss into the medium (section 2.5) and chondrocytes 
mediated nitrite production via Greiss reaction (section 2.4) . 
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2.2.2.4: Cartilage digestion 
Following 3 days of culture, cartilage post culture explants from the initial 
experiments were digested to measure their GAG concentrations. To prepare 
digestive medium containing papain, initially phosphate buffer was prepared by 
dissolving l 0.2g of sodium dihydrogen phosphate (Sigma 22-9903) in 170m! of 
double distilled water to produ~e O.SM solution. 11.2g of disodium hydrogen 
orthophosphate (Sigma 22-9905) was dissolved in 80ml of double distilled water 
to produce O.lM solution. These solutions were mixed together to give a total 
volume of 250m! and pH was adjusted to 7 by adding either more of acidic salts 
(sodium dihydrogen orthophosphate) or basic salts (sodium hydrogen 
orthophosphate). 326mg of N-acetyl cysteine (Sigma-A8199) was added to 
1 OOml of solution taken from 250ml of combined solutions and made upto 1 L by 
adding 900ml of double distilled water to prepare phosphate buffer. 
Digestive medium was prepared by adding 1 Omg of papain to phosphate buffer. 
Following the addition of 1 ml of digestive medium, cartilage discs contained in 
eppendorfs were incubated for 3 hours. This digested cartilage solution was 
analysed for GAG content (section 2.5). 
2.2.3: Fibroblast co-culture experiments 
Porcine nasal cartilage discs were weighed (30mg ± lOmg) and placed in 24 well 
tissue culture plates containing 80% confluent fibroblast monolayer and were 
incubated for 24 hours in lml of CSM. Varying concentrations of EPO in 
presence or absence of IL-l~ were administered to selected wells and the culture 
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media were replenished every 24 hours during 3-day time course studies. 
Following the collection of media supernatants in labelled eppendorfs cartilage 
discs were disposed off and fibroblasts were subjected to cell viability and densit 
measurements using Trypan blue exclusion assay (section 2.3) . The media 
supernatants were analysed for nitrite production (section 2.4) and GAGs release 
(section 2.5) . 
2.3: Trypan blue exclusion assay 
Trypan blue (Sigma T5526) (0.4%) solution was prepared in HBSS . Fibroblasts in 
24 well tissue culture plates, were trypsinized, centrifuged and resuspended in 2ml 
of HBSS (section 2.2.1.3) and 100111 of 0.4% trypan blue solution was added to 
100111 of cell suspension from each well into micro centrifuge tubes. Samples 
were left for 5 minutes to establish cell density per ml using eumberg 
haemocytometer. Cells containing blue dye were considered to be non-viable. 
Cell viability was measured and expressed as follows (.Kopac eta/., 2002): 
%Cell Viability = number of viable cells I total number of cells x 100 
2.4: Greiss reaction 
Nitric oxide is a short lived free radical that converts to nitrate and nitrite, which 
are the stable products of NO metabolism. NO was measured indirectly by 
measuring the concentration of nitrite, in tissue culture media from explant and 
fibroblast experiments via Greiss reaction. The Greiss reaction forms a 
chromogenic azo product in stoichiometric proportions to nitrite (Verdon et a/. , 
1995). 
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2.4.1: Preparation of sodium nitrite standards 
The Greiss reagents and nitrite standards were prepared as follows: 
Sodium nitrite (Sigma S2252) was used to produce a dilution series of sodium 
nitrite in double distilled water. Sodium nitrite standard (5mM) stock solution was 
prepared by dissolving 17.25mg of sodium nitrite in 50ml of double distilled 
water. A lml aliquot of 5mM stock solution was added to 9 ml of double distilled 
water in a clean sterile universal to produce 500f...lM/ml sodium nitrite solution. 
This was used to produce a final concentration range of sodium nitrite standard 
solution between 0-120 11M in 96 well plate. The absorbance of samples was 
measured at 540nm in 96 well plates to quantify nitrite production. A typical 
standard curve showing nitrite generation is shown in Fig. 2.4.1. 
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Fig. 2.4.1: A typical standard curve using 0-120 J.!M sodium nitrite standards 
to produce a linear regression equation 
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Fig. 2.4.1: Concentration of nitrite in culture media was determined by using a 
linear regression equation derived from plotting absorbance values fro m 0-
120J.!M/ml sodium nitrite standards. 
2.4.2: Preparation of Greiss reagents 
Nitrite production in tissue culture supernatants collected from cartilage 
fibroblasts and co-culture experiments was measured using sulphanilamide (SA) 
(Sigma S925 1) and (N- ( 1- Napthyl ethylene diamine) (NED) (Sigma N2 195). 
Glassware was washed with 70% IMS, then rinsed with double distilled water 
prior to use. 
A 1% w/v SA solution was prepared by dissolving O. l g of SA in 1Om I of 3M 
hydrochloric acid (HCI), prepared by diluting a 98% w/v solution of HCI using 
double distilled water. O.lg of NED was dissolved in 1Om I of double distilled to 
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produce a 1% w/v NED solution. Supernatant samples were allowed to defrost at 
room temperature before the quantification of nitrite. 
90J.ll of SA solution was added to 90J.1l of samples and standards in a 96 well plate 
and left in a dark area for 5 minutes . NED dissolved in double distilled water was 
added to samples and the standards in 90J.1l aliquots. The absorbance was 
measured using a UV /VIS plate reader at 540 nm. 
2.5: Glycosaminoglycan measurement (GAG assay) 
Cartilage degradation in arthritis involves a significant loss of proteoglycans from 
cartilage matrix and GAG is one of the integral proteoglycans that constitutes 
cartilage matrix . Chondroitin sulphates (CS) (Sigma C4384), also refered to as 
polysulphated GAGs (PS GAGs), are regarded as important components of 
cartilage matrix. Therefore, CS was used (Farndale et al., 1982) to produce a 
standard stock solution for the measurement of GAG concentrations. 
The supernatant samples, obtained from time course experiments were analysed 
for cartilage GAGs release following administration with various treatments. The 
reagents used for the assay, formate buffer and Dimethylene blue dye (DMB), 
were prepared as follows : 
2.5.1: Formate buffer 
2. 0 g of sodium formate (Sigma S2140) was dissolved in double distilled water 
and 0.25ml of 97% formic acid was added . The pH was adjusted to 5 using an 
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electronic pH meter by adding more sodium formate then made up to 500ml with 
double distilled water. 
2.5.2: 1,9 Dimethyl Methylene blue (DMB) 
8 mg ofDMB was dissolved in 2.5 ml of 100% ethanol before adding to 500ml of 
formate buffer. 
2.5.3: Measurement of GAG in supernatants and cartilage digest media 
To measure GAG concentration derived from cartilage cultured in vitro, l mglml 
of CS (extracted from shark cartilage) was dissolved in DMEM to use as a 
standard stock solution. 
Dilutions of CS at 5j..1.g intervals (0-50~tg/ml) were prepared to construct the 
standard GAG curve. A 40j..1.\ aliquot of sample was assayed for GAG release by 
the reaction with 200j..ll of DMB using a UV/VIS plate reader at 540nm. 
Concentration of GAG was determined by using a linear regression equation 
derived from plotting absorbance values from chondroitin sulphate standard . A 
typical standard curve is shown in Fig. 2.5.3: 
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Fig. 2.5.3:A typical standard curve using 0-50 jlg/ml CS standards to 
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Fig. 2.5.3: Concentration of GAGs in culture media was calculated by using a 
linear regression equation obtained from plotting absorbance values from 0-50 
~-tg/ml CS. 
Mean absorbance values from duplicate standards were used to plot the standard 
curve. This method was modified for measurement of GAGs content in po t-
culture cartilage explants . 
Post-culture cartilage explants were digested using papain in phosphate buffer 
medium (section 2.2.2.4) . The standard concentrations of CS between 0-
500~-tg/ml , with increments of 1 00~-tg/ml were prepared from the 1 mg/ml CS stock 
solution. A 40~-tl aliquot of cartilage digest medium was placed into a glass cuvette 
followed by addition of 2.5ml DMB solution. Absorbance was measured at 
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540nm usmg a UV/VIS Spectrophotometer. Mean absorbance readings of 
duplicate standards were used to plot the standard curve. Absorbance of each 
sample was measured twice and mean absorbance reading was calculated . 
Concentration of GAGs was measured using a linear regression equation derived 
from plotting absorbance values from CS standards, ranging between 0-500 ~g/ml 
ofCS. 
2.6: Statistical analysis of data 
The data obtained was expressed as the mean ± standard error of mean (SEM) . It 
was analysed using 2-tailed paired Student's t-test, and the difference was 
considered statistically significant when * P<0.05 ** P <0.01 *** P <0.001. 
Standard error was displayed on all histograms. 
Multiple t-tests were performed to compare the difference between vanou 
parameters and the difference was considered statistically significant when * 
P<O.OS ** P <0.01 *** P <0.001. 
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3.0: Introduction 
Cartilage breakdown has been shown to be under the control of chondrocyte-
derived chemical inflammatory mediators including ll.- 1, TNF and LPS in 
explant models. (Stefanovic-Racic et a/. , 1997; Bird et a/. , 1 997; Sandy el a/. . 
1999). However, several, other cell types including lymphocytes, acti vated 
macrophages and fibroblasts have also been reported to contribute in mediating 
inflammatory process and cartilage breakdown (Panagides and Tao 1978). 
Synovial fibroblasts are a major component of rheumatoid pannus tissue, which 
on interaction with endothelial cells and macrophages produce chemical 
mediators including NO, pro-inflammatory cytokines and MMPs (Ritchlin, 2000) . 
These compounds collectively function to modulate inflammation and joint 
destruction in RA. Therefore, fibroblasts seem to be the crucial regulators of joint 
inflammation and destruction in RA. 
The Swiss 3T3 fibroblast cell line, originated from mouse embryo (Green et a/. , 
1966), have been reported to produce NO on stimulation with IL-l~ (Burch el a/. , 
1989). Therefore, in this study a Swiss 3T3 fibroblast cell line was selected and 
stimulated with IL-l P to model the response of synovial fibroblasts found in 
pannus tissue of the rheumatic joint to EPO, which is commonly used to treat 
anemia associated with RA (see section 1. 8.1 ). 
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3.1 : Establishment of a Swiss 3T3 cell model of rheumatoid synovial 
fibroblasts 
Monolayers of Swiss 3T3 fibroblasts were grown to 80% confluence (see section 
2.7.1) and stimulated with lL-1~ and EPO. Medium was changed at 24 hour 
intervals over a time course of 3 days and supernatants were assayed for nitrite 
and GAG content. 
3.2: Effects of IL-1 ~ on nitrite production by Swiss 3T3 cells 
lL-1 ~ was employed, in a time course study by fibroblast monolayer, to 
investigate the optimum concentration required to induce nitrite production by 
fibrob last monolayer (Fig. 3.2.). 
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Fig. 3.2: Effect of IL-lP on nitrite production by Swiss 3T3 fibroblasts during 
a 3 day time course 
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Fig. 3.2: Time course of nitrite production by Swiss 3T3 fibroblasts (n=6) in 
tissue culture supernatant was measured during a 3 day period at 24 hour interval s 
following treatment with 10 and 20ng/ml ofiL-1 p. 
Swiss 3 T3 fibroblasts, which were exposed to 10 and 20ng/ml ll...-1 p fo r 24 h, 
produced between 1-2 !lmol/ml nitrite, following 1,2 and 3 days of culture. Peak 
nitrite production (2 ± 0. 1 ~tmol/ml) was measured on exposure to 1 Ong/ml ll...-1 P 
after one day of culture (Fig 3.2). This treatment increased nitrite production by 
300-400% compared to untreated control cells (p < 0.00 I). This effect wa 
reduced to below the basal level of untreated cell s following treatment with of L-
NAME (100!-!M) (data not shown). The nitrite production was approximately 15-
25% higher in l Ong/ml ll...-1 B treated group as compared to 20ng/ml ll...-1 B treated 
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group. Therefore, 1 Ong/ml concentration of IL-1 ~ was used 111 subsequent 
investigations on this cell model. 
3.3: Effects of EPO on nitrite production by Swiss 3T3 cells 
Time course dose response studies to 0.1,1,10,25,50 and IOOlJ.U/ml ofEPO were 
performed and nitrite production by fibroblast monolayer was measured (see 
section 2.1 .9). Selected results are illustrated in Figs. 3.3.1a-3.3 .1.c. (also see 
Appendix I) . 
Analysis of data using Student's t-test, assuming unequal variance showed that 
there was no statistical significant difference in nitrite production by fibroblasts 
on stimulation with EPO at 1 and 10 lJ.U/ml compared to respective control groups 
(see Appendix I) . However, a minor increase in nitrite production was measured 
following stimulation with O.llJ.U/ml ofEPO on day 2 and 3 oftime course study 
but this increased value was not statistically significant compared to control. 
Investigations were performed with a lower concentration range of EPO 
(0 .01 ,0.05 and O.llJ.U/ml) but they had no effect on nitrite production by 
fibroblast monolayer (data not shown). 
In second time course study a higher concentration of EPO (I OOlJ.U/ml) was 
employed and nitrite production by fibroblast monolayer was measured (Fig. 
3 .3.la). 
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3.3.1a: Effects of EPO (1,10 and 100 J..LU/ml EPO) on nitrite pr·oduction by 
Swiss 3T3 fibroblasts during a 3 day time course study 
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Fig. 3.3.1a: Time course of nitrite production by Swiss 3T3 fibroblasts (n=6) in 
tissue culture supernatant was measured during a 3 day period at 24 hour intervals 
following treatment I, 10 and IOO~tU/ml EPO. 
Treatment with 1 OOJlU/ml of EPO increased nitrite production, by approximately 
10-15%, compared to control following 1,2 and 3 days of culture. However this 
increased value could not achieve a statistical significance compared to controls. 
Therefore, a range of EPO concentrations (25,50 & I OOJlU/ml) were applied to 
see whether a peak effect of EPO on nitrite production by fibroblast monolayer 
lay between 10-100 ~tU/ml (Fig. 3.3.1b). 
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Fig 3.3.1b: Effects of EPO (25,50 and tOO JlU/ml EPO) on nitrite production 
by Swiss 3T3 fibroblasts during a 3 day time course study 
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Fig. 3.3.1b: Time course of nitrite production by Swiss 3T3 fibroblasts (n=6) in 
tissue culture supernatant was measured during a 3 day period at 24 hour intervals 
following treatment 25,50 and 1 OOJ.!U/ml EPO. 
The measurement of nitrite in culture media showed a significant increase 
(p:S:0.001) in nitrite production by Swiss 3T3 fibroblast monolayer following 
administration ofEPO (25J.!U/ml) compared to control group following 1,2 and 3 
days of incubation. Although, exposure of cells to higher concentrations of EPO 
(50 and lOOJ.!U/ml) also caused an increase in nitrite production following 2 and 3 
days of culture, like the previous experiment (Fig. 3.3.1a), again, these values did 
not achieve statistical significance compared to controls. 
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The optimum concentration of EPO (25J.!U/ml) was combined with IL-l~ 
(1 Ong/ml) and nitrite production was measured in the culture media (Fig. 3.3 . lc). 
Fig 3.3.1c: Effects ofEPO (25J..LU/ml EPO) and IL-l~ on nitrite production by 
Swiss 3T3 fibroblasts during a 3 day time course study 
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Fig. 3.3.1c: Nitrite production by Swiss 3T3 fibroblasts (n=8) in tissue culture 
media following treatment with 25J.!U/ml EPO, alone and in combination with IL-
1 ~ ' was measured during a 3 day time course study. 
Following treatment with 25J.!U/ml of EPO a significant increase (P~ 0.01) in 
nitrite production was detected, which was further increased in the presence of IL-
1 (Fig. 3.3 .1 c). This increase was not statistically significant, but followed the 
same general pattern of O.l-0.2J,lmollml increase in nitrite production following 
one, two and three days of cell culture. There was also a statistical significant 
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increase (P:$0.001) in nitrite production by EPO treated group compared to IL-l~ 
and EPO (25J..t.U/ml) combined with IL-l treated groups (see table 3.3.1c). 
Mean nitrite Production (J..Imol/ml) ± SEM 
Stimulants Day 1 Day2 Day 3 
EPO 0.78±0.07 0.76±0.05 0.50±0.08 
25J..1U/ml J..lmol/ml J..lmol/ml J..lmollml 
IL-l~ 1.62±0.08 1.48±0.08 1.4±0.07 
20ng/ml J..lmol/ml J..lmol/ml J..lmollml 
T-test P=0.00022 P=0.00013 P=O.OOOOI 
EPO & 1.80±0.04 1.59±0.07 1.50±0.09 
IL-l J..lmol/ml J .. l .. mollml J..lmollml 
T -test P=0.00025 P=0.00019 P=0.00002 
Table 3.3.1c: Comparison of EPO-mediated nitrite production by Swiss 3T3 
fibroblasts (n=8) to the IL-l~ and EPO combined with IL-l~ treated groups. 
3.4: Discussion 
It is well known that IL-l induces nitrite production, enhances the synthesis of 
human synovial fibroblasts and activates synoviocytes to synthesize and release 
collagenase, a modulator of matrix remodelling in RA (Inoue et a/. , 2001 ). The 
primary objective of this study was to establish a Swiss 3T3 cell model of 
rheumatoid synovial fibroblasts following stimulation with IL-l f3 and to 
determine if Swiss 3 TJ fibroblasts respond to IL- l~ and EPO with respect to 
nitrite production in culture media and would release GAGs into culture media. 
According to a study by Tsiganos et al. , (1982) Swiss 3T3 cells possessed GAG-
like moieties on the surface of their extra-cellular membrane. However, it was not 
clear whether these molecules would be released into the culture media and would 
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be detectable using GAG assay. Monolayers of fibroblasts were grown to 80% 
confluent and stimulated with IL-1 ~ and various concentrations of EPO in several 
investigations with the change of media at 24 hours interval during a time course 
of 3 days. Media supernatants were collected and GAGs release was measured . In 
this study GAGs were not detected in the culture media in control or cytokine 
treatment conditions. 
The current study produced minimum basal levels, (0.4-0.7 J..l.moles/ml) of nitrite 
in control media on days 1,2 and 3, which are in accordance with the findings of 
Stefanovic-Racic et al. , (1994) where the rabbit resting cultures of fibroblasts 
produced very little or no NO. 
Increased production of nitrite into culture media was indeed detected following 
stimulation with IL-l~ (Fig. 3 .2) . Fibroblasts and chondrocytes are the major 
collagenase producing cells and the production of these enzymes can markedly 
increase on exposure to pro-inflammatory cytokines (Krane et al. , 1 990). From 
these experiments, IL-l-stimulated Swiss 3T3 fibroblast monolayer appears to be 
a suitable simple model for investigating the effects of EPO on rheumatoid 
synovial fibroblasts activity in RA. 
The response of Swiss 3T3 fibroblast monolayer to varying doses of EPO was 
investigated over 3 days. The optimum concentration of EPO (25J..1.U/ml) was 
combined with lL-1 ~ and an enhanced nitrite production by fibroblast monolayer 
was measured (Fig. 3.3. 1 c). Although not statistically significant, a time 
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dependent decrease in nitrite production was consistently measured during the 3 
day time course studies. Cell viability was assessed to determine if fL-1 and EPO 
increased cell death in fibroblast rnonolayers. Cell viabilities were found to be 
between 80-90% in all cases. 
The present findings revealed that although EPO-induced nitrite production was, 
significantly less than IL-l B-induced production EPO may, nonetheless, 
unexpectedly contribute to NO production in this Swiss 3T3 cell model of 
rheumatoid synovial fibroblasts, the most important component of pannus tissue 
in RA. In order to further investigate this hypothesis similar sets of experiments 
were conducted using IL-l and EPO in cartilage explant models ofRA (chapter 4) 
and co-culture models (chapter 5). 
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CHAPTER 4: THE EFFECTS OF EPO AND IL-1 B ON PORCINE 
CARTILAGE EXPLANT MODEL 
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4.0: Introduction 
Previous studies have revealed that pro-inflammatory cytokines such as TNF-a, 
LPS and IL-l B, which are released by synovial cells and invading macrophages 
within an inflamed joint, mediate inflammation and promote cartilage degradation 
in explant models (Stadler et al. , 1991 ). Loss of proteoglycan from cartilage 
matrix is among the early stages of cartilage degradation in arthritis and GAG is 
one of the key proteoglycans of cartilage. 
In this chapter, the profile of IL- l-mediated nitrite production and GAGs release 
from older and younger (1-2 month old) porcine cartilage (3-4 month old) 
explants was studied over 7 days. The younger porcine cartilage explants were 
selected for use as an explant model of cartilage degradation due to their increased 
responsiveness to IL-l B with respect to NO production and GAG release from 
explants (section 4.1.2). 
Following the establishment of this explant model of cartilage degradation, the 
effects of other pro-inflammatory cytokines, such as TNF-a and LPS, and EPO 
were also investigated. The results obtained from this explant model of cartilage 
degradation were compared with those seen in Swiss 3T3 model of rheumatoid 
synovial fibrob lasts (chapter 3) and are discussed in section 4.4. 
4.1 :Effect of IL-1 J3 on porcine cartilage explants 
Porcine nasal cartilage explants were harvested from older (3-4 months old) 
(section 4.1.1) and younger (1-2 month old) animals (4.1.2), and these were 
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studied to obtain a 7 day profile of nitrite production and GAGs release into 
culture media, after stimulation with IL-lB . 
4.1.1:Effect ofiL-lf3 on older porcine cartilage explants 
Explants were pre-cultured in CSM prior to the addition of cytokines (designated 
as day 0), then treated as follows: a) control group, b) IL-lf3 (20ng/ml) (n=8). 
Culture media and treatments were replenished every 24 hours for a period of 7 
days (section 2.1.5). Supernatants were then analysed for the production of nitrite 
(section 2.1.9), post-culture GAG content in the cartilage and release of GAG 
from the cartilage (section 2.1.8). The results of these studies are shown in Fig. 
4 .1.1a, 4.1.1b and 4.1.lc. 
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Fig. 4.1.la: Effect ofiL-lB on nitrite production by older porcine nasal 
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Fig. 4.1.1a: Time course of nitrite production by porcine cartilage (n=8) in tissue 
culture supernatant was measured over 7 days, at 24 hour intervals, following 
treatment with il--l B (20ng/ml) . 
Previous studies by Stadler et a/., in I 991 showed that ll.--1 ~ stimulated the 
production of NO by articular chondrocytes. However, the current study did not 
detect a significant difference in nitrite production by IT.--1 B treated groups when 
compared to respective control groups, at 24 hour intervals, over a time course 
study. Following 7 days of incubation, the level of nitrite production steadily 
declined, decreasing by approximately 50% compared to day I . 
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Fig. 4.1.1b: Effect ofiL-lJ3 on GAG content in older post-culture cartilage 
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Fig. 4.1.1b: Porcine nasal cartilage explants (n=8) were treated with 20ng/ml of 
IL-l J3 over a 6 day incubation and cartilage GAG content was measured . 
Following 6 days incubation with IL-1 J3, the GAG concentration m porcme 
cartilage explants was determined to be between 750-850!-lg/ml/mg of cartilage, 
with no significant difference in GAG content compared to control group. 
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Fig. 4.1.1c: Effect of IL-l f3 on GAG released from older porcine cartilage 
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Fig. 4.1.1c: Time course of GAG release by porcine cartilage (n=8) 111 tissue 
culture media was measured at 24 hour intervals over 6 days following treatment 
with IL-l f3 (20ng/ml) . 
Like nitrite production by cartilage explants (Fig. 4. 1. 1 a), measurement of GAG 
in tissue culture supernatants (Fig.4.l.lc) declined steadily with time both in 
treated and untreated groups. By day 6, the level decreased by approximately 75 
% compared to day 0 in both treated and untreated groups. 
4.1.2:Effect of IL-lP on younger porcine cartilage explants 
Nietfeld et a!., (1990) showed that IL-l-mediated proteoglycan depletion was 
greater in younger human cartilage, and suggested that the young cartilage was 
more sensitive than the old human cartilage, with respect to its response to IL-l . 
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According to a study by Wong el al., (2001), both rabbit and porcme nasal 
cartilage models share similarity with their human counterpart which e tablishes 
these species as appropriate animal models for nasal septal cartilaginous surger . 
Thus, it was extrapolated that lL-1 P-stimulated proteoglycan release would be 
greater in younger than the older porcine cartilage. The effect of lL-1 p on the 
production of nitrite (Fig. 4.1.2a), GAG concentration in post-culture explants 
(Fig. 4.1.2.b) and release of GAG (Fig. 4.1.2.c) from explant cultures using young 
(approximately 1-2 month old) porcine cartilage was studied . A 7 day dose 
response profile of nitrite production and GAG release from young cartilage 
explant, to 10 and 20ng/mllL-l p was performed. The results are illustrated in Fig. 
4 .1.2a. 
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Fig. 4.1.2a: Effect of ll_;-1~ on nitrite production by young porcine nasal 
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Fig. 4.1.2a: Time course of nitrite production by porcine cartilage (n=8) in tissue 
culture supernatant was measured during a 6 day period at 24 hour interval s 
following treatment with 10 and 20ng/ml ofiL-Ip . 
The profile of nitrite production was different in younger than older explants . 
Following the treatment of cartilage explants with IL- l~ ( lOng/ml), nitrite 
production increased significantly (0 .07±0.005 and 0.062±0.0 I uM) as compared 
to untreated control group on day 2 and 3 respectively. However after 
stimulation with 20ng/ml of IL-lP, a highly significant increase (p<O.OOI ) in 
nitrite production was noticed as compared to respective control groups. Thi 
effect was consistently seen over 6 days. Peak nitrite production (0 .095±0.0 1 uM) 
was measured on exposure to IL-lP (20ng/ml) after 1 day of culture. A time 
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dependent decrease in nitrite production was observed. The basa l level of nitrite 
production on day 6 decreased by approximately 30% as compared to day 0. 
Fig. 4.1.2b: Effect of~-1 6 on GAG content in younger porcine nasal 
cartilage explant 
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Fig. 4.1.1 b: Porcine nasal cartilage ex plants (n=8) were treated with I 0 and 
20ng/ml of IL-l J3 during a 6 day incubation. Post-culture cartilage explants were 
digested and GAG content was measured . 
The concentration of GAG content in post-culture cartilage explants (Fig. 4.1.2 b) 
was approximately 1000-11 OOj..lg/ml/mg. This was approximately 10% higher 
than GAG concentration measured in post-culture cartilage explants from older 
pigs (Fig. 4.1.1 b) and remained unchanged like older post-culture cartilage 
explants following incubation with 10 and 20ng/m1 ofiL- lJ3 for 6 days . 
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Fig. 4.1.2c: Effect of IL-l~ on GAG release into the culture media from 
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Fig. 4.1.2c: Time course of GAGs release from porcine cartilage (n=8) in tissue 
culture supernatant was measured during a 7day period at 24hour intervals. 
GAG released into the cartilage media by cartilage explants was significantly 
increased on stimulation with IL-l~ (20ng/ml) (p<O. 001) compared to respective 
control groups over 6 days (Fig. 4.1.2c). However, no significant response was 
obtained with 1 Ong/ml of IL-l~ . A time dependent decline in the release of GAG 
was measured and on day 6 the basal levels of GAG release decreased by 
approximately 20% compared to day 0. Peak GAG release (2.1±0.0.01J..tg/mg/ml) 
was measured on exposure to 20ng/ml of IT.--1 ~ on day 2 of culture and this 
treatment increased the GAG loss by approximately 50-90% compared to 
untreated control and IL-l~ (1 Ong/ml) treated respective groups over 6 days. 
These results were in accordance with studies performed by Misra et a/. , (1999) 
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which showed that ll.,-1 ~ stimulated the release of GAGs from porcme na al 
cartilage explants. 
Since the young cartilage explants were more responsive to ~-1~ with respect to 
nitrite production and GAG release from the cartilage as contrast to older 
explants. Therefore, the young porcine cartilage explant model was used in 
successive studies. The effects of TNF-a and LPS were also investigated on 
porcine cartilage model in a 3 day time course study (section 4.2) . 
4.2: Effect of TN F-a on porcine cartilage explants 
TNF-a has been implicated as a mediator of inflammation (Stadler et a!. 1991 ), 
cartilage breakdown and has been linked to the reduction of proteoglycan 
synthesis in both young and old human articular cartilage explants (Wilbrink et 
a/., 1991). However, on a molar basis it is less potent than ll.,-1~ and both can act 
in synergistic fashion, and can also induce the production of each other and of 
other cytokines. 
The porcme cartilage explant model was stimulated with TNF-a (1 , 50 and 
1 OOng/ml) in a three day time course study, to investigate its effect on nitrite 
production (Fig. 4.2.1 a), post-culture cartilage GAG content (Fig. 4.2.1 b) and 
release of GAG (Fig. 4.2. Ic) from the cartilage. 
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Fig. 4.2.1a: Effect of TNF-a. on nitrite production by porcine nasal 
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Fig. 4.2.1a: Time course of nitrite production by porcine cartilage (n=8) in tissue 
culture supernatant was measured during a 3 day period at 24 hour intervals 
following treatment with TNF-a (1 ,50 and 1 OOng/ml). 
The level of nitrite production appeared to decline with time and on day 3 it 
decreased by approximately 50% compared to day I . Exposure of cartilage 
explants to lower concentration of TNF-a. (1 ng/ml) caused a statistical significant 
(P~ 0.05) increase in nitrite production compared to control on day 3. However, 
this statistically significant increase was not consistent over 1 and 2 days of 
culture. 
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Fig. 4.2.1b: Effect ofTNF-a on GAG content in porcine nasal cartilage 
explant 
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Fig. 4.2.1b: Porcine nasal cartilage explants (n=8) were treated with 1 50 and 
lOOng/ml of TNF-a.during a 3 days incubation .The post-culture cartilage 
explants were digested and GAG content was measured . 
The concentration of GAG content in post-culture cartilage explants was 
approximately 1000-llOO!J.g/ml/mg and this did not change following incubation 
with 1, 50 and 100ng/ml ofTNF-a. 
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Fig. 4.2.1c: Effect of TNF-a on GAG release into the culture media from 
porcine nasal cartilage in a time course study during 3 days 
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Fig. 4.2.1c: Cartil.ages were pre-cultured for 24 hours (n=8) (labelled as dO) prior 
to addition of TNF-a (1, 50 and 100ng/ml). Media was collected every 24 hours 
for 3 days and the release of GAG was measured following treatment with TNF-a 
1, 50 and lOOng/ml. 
Analysis of data usmg Student's /-test showed that there was no significant 
difference observed in GAG release between control and treated groups. 
Although not signjficant compared to control, an increase in GAG release 
(0 . 89±0.05~mol/ml to 0 . 95±0 . 08~mol/ml) and (0.91±0.06!Jmol/ml to 
0.99±0.06!Jmol/ml) was measured following stimulation with 50ng/ml of TNF-a 
on day 1 and 2, respectively of time course study. The release of GAG on day 2 
decreased by 15-20% compared to day 1 and it increased by 15-20% on day 3 
compared to day 2. 
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In this study TNF-a did not influence GAG profiles in post-culture cartilage 
explants (Fig. 4 .2.1b) or in culture media (Fig. 4.2.1c). However, Inglml ofTNF-
a produced a statistical significant (P:s;O.OS) elevation (0.054±0.003JlmoVml) in 
production of nitrite compared to control (0.046±0.002J.1.moVml) on day 3 of 
culture (Fig. 4.2.1 a) . Therefore, it was speculated that a concentration range lower 
than 1 ng/ml of TNF-a may induce a response by porcine cartilage explant model. 
Likewise, TNF-a can be a more potent inflammatory stimulus than IL-l P on a 
molar basis in this type of cartilage. 
4.3: Effect of LPS on porcine cartilage explants 
LPS is a bacterial endotoxin that promotes joint inflammation associated with RA. 
Various studies have demonstrated that LPS stimulates NO production in 
chondrocytes. Ralston et al. , (1994), reported the production of NO and the 
expression of iNOS in human osteoblasts, following LPS stimulation. 
Porcine nasal cartilage explants were stimulated with 1, 10 and 1 OOJ.lg /ml LPS to 
produce a dose response curve profile of nitrite production and GAGs release. 
Stadler et a/. , (1991) and Morales et al., (1989) used these concentrations in 
studies carried out with cartilage chondrocytes. GAGs were measured in the 
culture media to determine if porcine cartilage explants released GAGs on 
stimulation with LPS (Fig. 4.3c). LPS-induced nitrite production by cartilage into 
culture media (Fig. 4.3. la) and the concentration of GAG in post culture cartilage 
explants were also measured (Fig. 4.3.1b). Similar results were obtained, as those 
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seen with TNF-a stimulation with respect to nitrite production and GAGs 
measurement. 
Fig. 4.3.1a: Effect ofLPS on nitrite production into the culture media by 
porcine nasal cartilage in a time course study during 3 days 
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Fig. 4.3.1a: Time course of nitrite production by porcine cartilage explants 
(n=8) in tissue culture supernatants was measured during a 3 day time period at 
24 hour intervals following treatment with 1,10 and lOO!lg/ml ofLPS . 
No significant difference observed between control and treated groups at all 
measured time points (Fig. 4.3. la). However, the production of nitrite in 
culture media by cartilage explants in both treated and untreated groups over 
three days followed a bell shaped curve. On day 2 nitrite production increased 
by, approximately 25%, compared to day 1 and this value decreased by 
approximately 50% on day 3. 
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Fig. 4.3.1b: Effect ofLPS on GAG content in porcine cartilage explant 
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Fig. 4.3.1b: Porcine nasal cartilage explants (n=8) were treated with 1, 10 and 
1 OOg/ml ofLPS during a 3 days incubation . . The post-culture cartilage explants 
were digested and GAG content was measured. 
The incubation of cartilage explants in 1 00/lg/ml of LPS caused an increase in 
GAG content of cartilage however, this increased value did not gain statistical 
significance compared to control. 
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Fig. 4.3.lc: Effect of LPS on GAG release into the culture media from 
porcine nasal cartilage in a time course study during 3 days 
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Fig. 4.3.lc: Time course of GAGs release from porcme cartilage (n=8) in 
tissue culture supernatant was measured during a 3 day period at 24hour 
intervals following treatment with LPS 1, 50 and lOOflg/mL 
No significant difference observed between control and treated groups at all 
measured time points (Fig. 4.3.1c). On day 2, approximately 2-5%, increase in 
GAG release was measured as compared to day 1 and this value decreased by 
approximately 5-7%, on day 3. 
The apparent deviations from the dogma that LPS and TNF mediates cartilage 
breakdown may have been a result of cartilage species variability in response to 
treatment with inflammatory mediators. In porcine cartilage explant model IL- 1 p 
proved to be the most potent inflammatory mediator, as was seen in fibroblast 
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monolayer model (chapter 3). EPO increased the production of nitrite by 
fibroblast monolayer, however, no GAGs was detected in fibroblast cell culture 
media. Therefore it would be interesting to see if porcine cartilage explant model 
would respond to EPO stimulation, with regard to nitrite production and GAGs 
release (section 4.4). IL-l~ was chosen as a positive control stimulus in the 
cartilage explant model to compare with the effects ofEPO on cartilage explants. 
4.4: Effect of EPO on porcine nasal cartilage explant model 
In a series of 3 day time course studies, the cartilage explant model was stimulated 
with a wide range of concentrations ofEPO (0.1 , 1, 10, 25, 50 and IOOj.lU/ml 
EPO). Culture media was collected every 24 hours over 3 days and analysed for 
the production of nitrite and the release of GAGs from cartilage explants. The 
results for nitrite and GAGs measurement following stimulation with 0.1, I and 
1 Oj.lU/ml ofEPO are illustrated in Appendix II and III respectively. 
Analysis of data using Student's t-test, assuming unequal variance showed that 
there was no significant difference observed between control and treated groups 
over 3 days. However, EPO at 1 and 1 O!J.U/ml, produced higher levels of nitrite 
following 2 and 3 days of culture but this effect was not consistent and failed to 
attain a statistical significance compared to control (see Appendix II) . Similarly 
after stimulation with 1 O!J.U/ml of EPO on day 1 and 3 of time course study a 
minor increase in GAGs release was noticed but this increase was not statiscially 
significant compared to control (see Appendix III) . 
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Post-culture cartilage explants were also analysed for their GAG content 
following incubation with EPO but there was no significant difference observed 
between treated and untreated groups as was seen previously after stimulation 
with IL-l~, TNF-a and LPS. 
Cartilage explants were stimulated with 1, 25, 50 and lOOJ.!U/ml of EPO and the 
results for nitrite and GAGs measurement are depicted as Fig. 4.4 .la and 4.4.1 b 
respectively. 
Fig. 4.4.1a: Effect of EPO (1, 25, 50 & 100 f..I.U/ml) on nitrite produced by 
cartilage explants into culture media in a time course study over 3 days 
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Fig. 4.4.1a: Cartilage was isolated from porcine noses and cultured in vitro (n=8) 
for 24 hours prior to addition of EPO (1 , 25, 50 and 1 OOJ.!U/mJ) and IL-1 ~ 
(20ng/ml). Culture media was analysed for nitrite production following 3 days of 
culture. 
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The optimum concentration ofEPO required to induce the production of nitrite b 
cartilage explants was measured to be 25J..LU/ml. IL-l ~-induced nitrite production 
was higher than EPO-induced production following 1 and 2 days of culture 
however, there was no statistical significant difference observed between these 
groups (Table 4.4.1a). EPO (1 ,50 and lOOJ..LU/ml) failed to have an effect on the 
production of nitrite by cartilage explants. 
Mean nitrite Production (J..Lmol/ml) ± SEM 
Stimulants Day 1 Day 2 Day 3 
EPO 0.089±0.004 0.093±0.007 0.094±0.004 
25J..LU/ml J..Lmol/ml ~-tmol/ml J..Lmol/ml 
IL-l~ 0.] 08±0.02 0.] 06±0.012 0. 095±0.01 
20ng/ml J..l.mOl/mJ J..Lmol/ml J..l.mol/ml 
T-test P=0.20 P=O.l9 P=0.26 
Table 4.4.la: Companson of EPO and IL-l mediated mtnte production by 
Porcine cartilage explants (n=8). 
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Fig. 4.4.1b: Effect ofEPO (1, 25,50 & 100 llU/ml) on GAGs released into the 
culture media from porcine nasal cartilage during a 3 day time course 
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Fig. 4.4.1b: Cartilage was isolated from porcine noses and cultured in vitro 
(n=8) for 24 hours prior to addition of EPO (1 , 25, 50, and IOOJ..LU/ml) and rL-1 P 
(20ng/ml). Culture media was analysed for release of GAGs following 3 days of 
culture. 
The optimum concentration of EPO to induce a significant effect on cartilage 
metabolism was found to be 25J..LU/ml. EPO (1 and IOOJ..LU/ml) did not have an 
effect on the release of GAGs from cartilage explants. EPO at 501J.U/ml increased 
GAGs release (I .1± 0.08J..Lg/ml) from cartilage explants, which was much less 
than GAGs release (1 .2±0. l!J.g/ml) caused by 25 J..LU/ml of EPO. However it could 
not attain a statistical significance compared to control. IL- l P-induced GAGs 
release was higher than EPO-induced release following 1 and 2 days of culture, 
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however, there was no statistical significant difference observed between these 
groups (Tab le 4.4.1b) 
Mean GAGs release (!lg/mg)/ml ± SEM 
Stimulants Day 1 Day2 Day3 
EPO 1.2±0.09 1.12±0.05 1.25±0.06 
25!-lU/ml (j.lg/mg)/ml (!lg/mg)/ml (!lghng)/ m I 
IL-1!3 1.42±0.09 1.22±0.05 1.25±0.03 
20ng/ml j.lmol/ml j.lmollml j.lmol/ml 
T-test P=0.10 P=0.15 P=0.26 
Table 4.4.1b: Comparison of EPO and IL-l mediated GAGs release by porcme 
cartilage explants (n=8). 
The 25!-lU/ml concentration ofEPO was combined with IL-1!3 and their combined 
effects on nitrite production (Fig. 4.4.lc) and GAG release (Fig. 4.4.ld) were 
analysed. 
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Fig. 4.4.1 c: Effect of EPO in the presence of IL-113 (20ng/ml) on nitrite 
production by porcine nasal cartilage in a time course study over 3 days 
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Fig. 4.4.1.c: Cartilage was isolated from porcine noses and cultured in vitro (n=8) 
for 24 hours prior to addition of EPO and ~- 113 (20ng/m1). Culture media was 
analysed for nitrite production following 3 days of culture. 
Administration of EPO (25j.!U/ml) and IL-113 (20ng/ml) over 3 days resulted in a 
consistently significant increase (p<O.OS and p<O. Ol , respectively) in nitrite 
production as compared to controL Enhanced nitrite production was measured 
following a combination treatment of EPO and ~-113 . Nitrite production by~-
and EPO combined treatment group was significantly higher than both IL- 1 and 
EPO treated groups alone. (Table 4.4.1 c). 
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Mean nitrite Production (J.lmol/ml) ± SEM 
Stimulants Day I Day 2 Day 3 
EPO 0.085±0.006 0.07±0.004 0. 068±0. 004 
25~-tU/ml J.lmol/ml J.lmol/ml ~Lmol/ml 
IL-l+EPO 0.122±0.007 0.012±0.008 0.095±0.009 
~tmol/ml ~-tmol/ml ~-tmo l/ml 
T-test P=0.005 P=O.Ol P=O.OOI 
1L-1+EPO 0.122±0.007 0.012±0.008 0.095±0.009 
~-tmol/ml ~-tmol/ml J.lmol/ml 
IL-lP 0. 096±0. 006 0.075±0.004 0.082±0.004 
20ng/ml J.lmol/ml J.lmol/ml J.lmol/ml 
T-test P=O.Ol P=O.Ol P=0.06 
Table 4.4.1c: Companson of EPO+IL-1-medtated mtnte productiOn to IL- l and 
EPO treated groups alone. 
Measurement of GAGs release from cartilage explants produced a similar profile 
(Fig. 4.4.1 d). 
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Fig. 4.4.1 d: Effect of EPO in the presence of IL-l B (20ng/ml) on release of 
GAGs from porcine nasal cartilage in a time course study over 3 days 
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Fig. 4.4.1d: Cartilage was isolated from porcine noses and cultured in vitro (n=S) 
for 24 hours prior to addition of EPO (25J..t.U/ml) and IL-lP(20ng/m1). Culture 
media was analysed for release of GAGs following 3 days of culture. 
EPO and IL-IP caused a significant (1.9±0.15 and 2.1±0.1J..Lg/ml, respectively) 
release of GAGs from cartilage explants compared to control ( l.5±0.l7J..Lg/ml). 
However, there was no significant difference observed between GAGs released by 
IL-l and EPO treated groups. The release of GAGs was enhanced in combined 
treatment of EPO and IL-lP (3 .2±0.3J..Lg/ml) as compared to group treated with 
EPO and lL-1 B alone (1.9±0. 15 and 2. l±O. IJ.lg/ml, respectively) (Table 4.4.1d). 
98 
Mean GAGs release (J...lg/mg)/ml ± SEM 
Stimulants Day l Day2 Day 3 
EPO 1.9±0.15 1.81 ±0.16 1.80±0.14 
25jlU/ml (J...lg/mg)/ml ( jlg/m_g}/ml ~m_g}/ml 
IL-1 +EPO 3.2±0.3 2.75±0.19 2.7±0. 12 
(J...lg/mg)/ml (J...lg/mg)/ml (~Lg/mg)/ml 
T-test P=0.0008 P=0.0007 P=0.0001 
IL-1 +EPO 3.2±0.3 2.75±0.19 2. 7±0.12 
(J...lg/mg)/ml (J...lg/mg)/ml (J...lg/mg)/ml 
IL-1P 2.1±0.1 1.84±0.14 1.83±0. 16 
20ng/ml (J...lg/mg)/ml (J...lg/mg)/ml (J...lg/mg)/ml 
T-test P=0.0007 P=0.0006 P=O.OOOI 
Table 4.4.1d: Companson ofEPO+IL-1-mediated GAGs release to IL-l and EPO 
treated groups alone. 
Nomega-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, was 
employed to inhibit EPO and IL- l P-mediated nitrite production. The effects of L-
NAME on nitrite production by IL-1 p and EPO and GAGs release from cartilage 
were investigated (see Fig. 4.4.1e and 4.4.1f, respectively) . 
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Fig. 4.4.1e: Effect of L-NAME on inhibition of nitrite production by cartilage 
explants on stimulation with EPO and IL-lP during 3 day time course 
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Fig. 4.4.1e: Cartilage was isolated from porcine noses and cultured in 'ifro for 24 
hours prior to addition ofEPO, IL- l p (20ng/ml) and L-NAME (1 OOJ.!M). Culture 
media was analysed for nitrite production following 3 days of culture. 
Both EPO and IL-l P-mediated production of nitrite was suppressed by L-NAME 
below to basal level of untreated control group. L-NAME also inhibited the nitrite 
production following stimulation ofEPO combined with IL-lP . 
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Fig. 4.4.1f: Effect of L-NAME on GAGs production by cartilage explants on 
stimulation with EPO in the presence or absence of IL-l f3 during 3 days 
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Fig. 4.4.1f: Cartilage was isolated from porcine noses and cultured in vitro (n=8) 
for 24 hours prior to addition ofEPO, ll.--1(3 (20ng/ml) and L-NAME (IOOJ.!M). 
Culture media was analysed for GAGs release following 3 days of culture. 
L-NAME had no significant effect on basal GAGs release from the cartilage. L-
NAME, decreased (p<0.05) ll.--1(3 and EPO-mediated GAGs release from the 
cartilage on day 1 compared to IT--I f3 and EPO treated groups, but this effect was 
not consistent over 3 days. However, it significantly (p<0.001 and p<0.01) 
inhibited the release of GAGs from the cartilage, on stimulation with EPO 
combined with ll.--1 f3 on day 2 and 3, respectively (see Fig. 4.4.1 f). 
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Mean GAGs release (J.lg/mg)/ml ± SEM 
Stimulants Day 1 Day2 Da_y_ 3 
IL-l 20ng/ml 1.59±0.06 1.58±0.06 1.57±0.04 
(J.lg/mg)/ml (J.lg/mg)/ml (gg{m_g}( ml 
L-Name 1.21±0.08 1.49±0. I 7 1.39±0. I 6 
lOO!lM+IL-1 (J.lg/mg)/ml (J.lg/mg)/ml (J.lg/mg)/ml 
T-test P=O.OOI P=0.13 P=0.09 
EPO 25!lU/ml 1.6±0.09 1.59±0.03 1.55±0.07 
(J.lg/mg)lml (J.lg/mg)/ml (gg{m_g}f ml 
L-Name 1.22±0.23 1.59±0.14 1.26±0.11 
IOO!lM+EPO (J.lg/mg)/ml (J.lg/mg)/ml (J.lg/mg)/ml 
T-test P=0 .05 P=0.23 P=0.003 
EPO+IL-1 1.82±0.15 1.93±0.06 1.98±0.14 
(J.lg/mg)/ml (J.lg/mg)/ml (J.lg/mg)/ml 
EPO+IL-1 1.31±0.38 1.38±0.17 1.4±0.26 
+L-Name (J.lg/mg)/ml (J.lg/mg)/ml (J.lg/mg)/ml 
T-test P=0.71 P=0.003 P=0.05 
Table 4.4.lf: Effect ofL-Name on EPO and IL-l-mediated GAGs release over a 
3 day time course study. 
4.5: Discussion 
Both younger (l-2month old) and older (3-4 month old) porcine nasal cartilage 
explants were tested with IL-l p to develop a model of cartilage degradation in 
RA. However, the young porcine nasal cartilage explants were selected to model 
the cartilage degradation due to its increased responsiveness to IL-l P regarding 
nitrite production and GAGs release. This model was stimulated with TNFa and 
LPS, which are the inflammatory mediators, and have previously been used in 
both in vitro and in vivo models of cartilage degradation. These mediators have 
been shown to induce the production of other inflammatory mediators (Hanglow 
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et al. , 1995; Stefanvoic-Racic et al. , 1997; Bird et al., 1997) (see section 
1.5.1.3.3). Nevertheless, they failed to induce a significant response in this type 
of cartilage. 
In this study, nitrite production was quantified as the response of chondrocytes to 
the inflammatory stimulus and GAGs were measured as an indicator of cartilage 
degradation. The results of this study show that stimulation of porcine cartilage 
explant cultures with EPO (25~U/ml) is independently able to elevate nitrite (Fig. 
4.4 .1a) and GAG (Fig. 4.4 .lb) levels within the culture media in this explant 
model. A similar response, of increased nitrite concentration (0 . 78±0 . 08~mol/ml, 
Fig. 3.3.ld) compared to porcine model (0 . 085±0 . 006~mol/ml, Fig.4.4.1a), was 
measured in 3T3 fibroblast model (chapter 3). Combined treatment of EPO 
(25~U/ml) and lL-1P (20ng/ml) increased nitrite levels (Fig. 4.4.lc) and caused a 
proportionate increase in GAG (Fig. 4.4.1d) release into culture media as 
compared to the treatments alone. A similar response, of increased nitrite 
concentration (1.82±0 . 05~mol/ml, Fig. 3.3.1c) was achieved by fibroblast 
monolayer model as compared to porcine explant model (0.12±0.007~mol/ml, 
Fig. 4.4.1d). In addition, the concentrations of 0.1, 1, 10, 50 and lOO~U/ml of 
EPO failed to cause a statistically significant change in nitrite production by both 
cartilage explant and fibroblast monolayer models (chapter 3). 
It has been demonstrated that extended exposure of endothelial cells to rHuEPO 
induces NOS activity (Benerjee et al., 2000), which implies that in this model 
rHuEPO (25~U/ml) may stimulate NOS activity that accordingly generates NO in 
the culture media. 
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The current investigation reported that EPO-induced nitrite production could be 
inhibited by L-Name, a non-specific NOS inhibitor (Fig.4.4.1 e) . This suggests the 
implication of NOS activity in EPO-induced nitrite production. Interestingly, in 
the present study, IL-l and EPO-induced GAGs release decreased in the presence 
of L-Name (1001-!M) as compared to EPO and IL-1!3 treatments alone (Fig. 
4.4.1±). However, this decreased GAGs release was not consistent, and 
statistically significant compared to EPO and IL-l !3 treatments alone following 2 
and 3 days of culture. This implies that NOS-activated NO production, is at least 
partially involved in EPO and IL-l !3-mediated GAGs release from cartilage. 
Unlike fibroblast monolayer model the present study did not show a statistical 
significant difference in nitrite production between IL- l !3 and EPO treated groups. 
This suggests that EPO and IL-l P may follow a similar route to NO production in 
porcine cartilage explant model. A possible mechanism through which rHuEPO 
stimulates NOS activity may be by inducing the expression of iNOS gene that 
leads to synthesis of iNOS enzyme which derives NO from L-arginine. Recent 
work has shown that pro-inflammatory cytokines stimulate NO production in vitro 
by activation ofiNOS pathway (Grabowski et al., 1997). 
The porcine cartilage explant model was integrated with fibroblast monolayer and 
a co-culture system was developed to study the effects of IL-l P and EPO on 
chondrocyte-mediated cartilage resorption and fibroblast-mediated cartilage 
breakdown (chapter 5). 
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CHAPTER 5: THE EFFECTS OF EPO AND IL-1 B ON 
CARTILAGE BREAKDOWN IN A CO-CULTURE MODEL 
USING PORCINE CARTILAGE AND SWISS 3T3 
FIBROBLASTS 
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5.0: Introduction 
The effects of ~-1 J3 , EPO, and the combined effects of EPO and ~-1 J3 , on 
fibroblast monolayer and cartilage explant models ofRA were discussed in 
chapters 3 and 4, respectively. This chapter describes the establishment of a co-
culture model of RA in which Swiss 3T3 fibroblasts were co-cultured with 
porcine nasal cartilage explants to model both the resorption of cartilage 
(mediated by chondrocytes) and the destructive effect (mediated by fibroblasts) in 
a rheumatoid joint. 
The objectives were therefore that of earlier models (chapter 3 and 4), i.e. to 
measure nitrite production and GAGs release in co-culture supernatants, over 3 
day time course studies. The results are compared with those obtained from 
experiments using fibroblast monolayer (chapter 3) and cartilage explants (chapter 
4) . 
5.1: Effect of IL-1J3 on porcine cartilage co-cultured with fibroblasts 
Fibroblasts were grown as a monolayer to 75% confluence, prior to the addition of 
porcine cartilage explants. The two systems were then pre-cultured for 24 hours in 
lml ofCSM, prior to the addition of~-IJ3 (10 and 20ng/rnl). The cartilage media 
and treatments were replenished every 24 hours for 2 days . The supernatant 
samples were assayed for nitrite production (section 2.1.9.) and GAG release 
(section 2.1.8.). The results for nitrite production and GAGs release are illustrated 
as Fig. 5.1.1 and 5.1.2, respectively. 
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5.1.1: Effect of IL-113 on nitrite production by co-cultures 
Fig. 5.1.1: Effect of IL-113 on nitrite production by porcine cartilage explants 
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Fig. 5.1.1 : Time course of nitrite production into culture media by porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6) was measured during a 3 
day period at 24 hour intervals. 
Co-cultured explants were pre-cultured for 24 hours prior to the addition of IL-1 P 
(designated as dO). Following exposure to 10ng/ml ofiL-1P, cartilage co-cultured 
explants released approximately 30-40% more nitrite compared to controls both 
on day 1 (0.52± 0.03 to 0.86 ± 0.08 J.tmollml, p<0.001) and day 2 (0.50 ± 0.08 to 
0.79 ± 0.08 ~-tmollml, p<0.001). Peak nitrite production (1.9 ± 0 . 1~-tmol/ml) was 
detected on day 1 following exposure of co-cultures to 20ng/ml of IL-l {3, a four 
fold increase over the control group. 
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5.1.2: Effect ofiL-113 on GAGs release from co-cultures 
Fig. 5.1.2: Effect ofiL-113 on GAGs released from porcine cartilage co-
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Fig. 5.1.2: Time course of GAGs released into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 
day period at 24 hour intervals 
Co-cultured explants were pre-cultured for 24 hours prior to the addition of IL-l 
(designated as dO) . !L-IP-induced GAGs release from co-cultured explants 
followed the same general pattern as was seen for nitrite production (see Fig. 
5.1.1) over 3 days of culture. Following 24 hours of culture, cartilage co-cultured 
explants exposed to lOng/ml IL-l~ released 1.55± 0.091J.g/ml of GAGs, i.e. 30-
40% more GAGs compared to controls (1.13± 0.181J.glml, p<0.001). Interestingly, 
like IL-l 13-induced nitrite production, peak GAG loss was measured on exposure 
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to 20ng/ml IL-1P on day 1 (2.51 ± O.l2J..Lg/ml, p<O.OOI ) of culture, increasing 
GAG release into the medium by approximately two fold, compared to control. 
The porcme nasal cartilage explants following the addition to fibroblast 
monolayer were pre-cultured for 24 hours in the initial experiments to determine 
the basal release of GAGs and nitrite production in a co-culture system. Since 
there was no difference in the level of both GAGs release and nitrite production in 
control groups on day 0, the pre-culture media was not analyzed for nitrite 
production and GAG release in later experiments. The time course studies were 
extended to another day following addition of treatments. 
5.2: Effect of EPO on co-culture explants 
Time course studies were carried out to obtain a dose response profile of nitrite 
production (5.2.1) and GAGs release (5.2.2), from co-cultures exposed to 0-
1 OOJ..LU/ml of EPO over 3 days. Among the different concentrations analysed for 
their effect on co-culture explants, were 0.1, 1, 10, 25, 50 and 100J..LU/ml ofEPO. 
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5.2.1: Effect ofEPO on nitrite production by co-cultured explants 
Fig. 5.2.1a: Effect ofEPO on nitrite production by porcine cartilage 
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Fig. 5.2.1a: Time course of nitrite production by porcme nasal cartilage co-
cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 day period at 
24 hour intervals. 
Exposure of co-cultures to EPO at 0.1 , 10 and 100~U/ml (Fig. 5.2.1a) failed to 
induce any measurable increase in nitrite production compared to untreated 
control groups (0.52± 0 . 03~mol/ml) . However, the group treated with 1~U/ml of 
EPO showed a small(< 15%) increase in nitrite production on day 2 (from 0.48± 
0.03 to 0.55± 0 . 04~-tmol/ml, p<0.05) and 3 (from 0.46± 0.04 to 0 . 54±0 .02~-tmol/ml , 
p<0.05) of culture. 
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Further experiments showed that exposure of cultures to 25JlU/ml of EPO 
increased nitrite production compared to control group over 3 days of culture (see 
Fig. 5.2.Ib). 
Fig. 5.2.lb: Effects of (25, 50& 100 JJ.U/ml) of EPO on nitrite production by 
porcine cartilage co-cultured with fibroblasts over a Jday time course 
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Fig. 5.2.lb: Time course of nitrite produced into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts n=6), was measured during a 3 
day period at 24 hour intervals. 
As in previous studies (chapter 3 and 4) the 25JlU/ml ofEPO was found to be the 
optimum concentration required to induce a response. The peak effect was 
measured on day I (Fig. 5.2.Ib) where treatment with 25JlU/ml ofEPO increased 
nitrite production approximately three fold from 0.64± 0.03Jlmol/ml in controls to 
I. 78 ± 0.05Jlmol/ml (p<O.OOI) in treated group. The magnitude of the effect of 
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EPO was therefore comparable to that measured following exposure of co-
cultures to 20ng/ml IL-lB (see Fig 5.2.1b. and 5.1.1). The supernatant samples 
were also analyzed for GAG loss. 
5.2.2: Effect of EPO on GAG release from co-cultured explants 
Fig. 5.2.2a: Effect of EPO on GAGs released from porcine cartilage co-
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Fig. 5.2.2a: Time course of GAGs released into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 
day period at 24 hour intervals. 
A similarity in the general pattern of GAG release to that of nitrite production was 
previously seen following treatment of co-cultures to IL-lP (section 5.1). The 
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same general similarity of pattern of nitrite production and GAGs release was 
measured in co-cultures treated with EPO. Treatment of co-cultures with lJ...LU/ml 
ofEPO slightly increased GAG release as compared to control groups over 3 days 
of time course study. This increase (1.32±0.05 to 1.5±0.07J...Lg/ml) was statistically 
significant (p<0.05) on dayl (Fig 5.2.2a). 
Fig. 5.2.2b: Effects of(25, 50 & 100 f..l.U/ml) ofEPO on GAGs released from 
porcine cartilage co-cultured with fibroblasts during 3day time course 
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Fig. 5.2.2b: Time course of GAGs released into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 
day period at 24 hour intervals. 
Following exposure of co-cultured explants to 25, 50 and lOOJ...LU/ml EPO, again 
the GAG release (Fig 5.2.2 b) also followed the same general pattern as that of 
nitrite production (Fig 5.2.1 b). 
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5.3: Combined effects of IL-1 ~ and EPO on co-culture explants 
The optimum concentration of 25~U/ml of EPO was combined with lL-1 ~ and 
their combined effects were investigated on co-cultured explants with respect to 
nitrite production (Fig. 5.3. I) and GAGs release (Fig. 5.3.2). 
5.3.1: Combined effects of IL-l~ and EPO on nitrite production by co-
cultured explants 
Fig. 5.3.1: Effect of25 JlU/ml ofEPO combined with IL-l~ on nitrite 
production by porcine cartilage co-cultured with fibroblasts over a 3 day 
time course 
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Fig. 5.3.1: Time course of nitrite production into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 
day period at 24 hour intervals. 
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This Fig 5.3.1 shows that exposure of co-culture explants to 25~J,U/ml of EPO 
combined with IL-l f3, appeared to be augmentative. Peak nitrite production was 
measured on day 1 of incubation. As in previous studies, 25~J,U/ml of EPO 
significantly (p<O.OOl) increased nitrite production compared to controls both on 
day 1 (0.6±0 . 08~J,mol/ml to 1.65±0.07~J,mol/ml) day 2 (0.5±0.08!-!mol/ml to 
1.55±0.07!-!mol/ml) and day 3 (0.48±0.07 !lmol/ml to 1.48±0.08!-!mol/ml). This 
was slightly less than IL-l f3 alone (I. 77±0.08!-!mol/ml) but not as great as 
combined treatments (2.1±0.07!-!mol/ml). This general pattern was seen over all 3 
days of incubation. 
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5.3.2: Combined effects of IL-113 and EPO on GAGs release from co-cultured 
ex plants 
Fig. 5.3.2: Combined effects of25J.1U/ml ofEPO with IL-113 on GAGs release 
from porcine cartilage, co-cultured with fibroblasts during 3 day time course 
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Fig. 5.3.2: Time course of GAGs released into culture media from porcine nasal 
cartilage co-cultured with Swiss 3T3 fibroblasts (n=6), was measured during a 3 
day period at 24 hour intervals. 
The general pattern of GAG release (Fig 5.3.2) closely resembled that of nitrite 
production (Fig 5.3.1) following exposure of co-cultured explants to 251-lU/ml of 
EPO, in combination with IL-113 over 1,2 and 3 days of culture. Exposure of co-
cultures to both IL-l f3 and EPO was approximately 25-30% higher than single 
treatments in all cases over three days. 
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5.4: Discussion 
Porcine cartilage explants were integrated with Swiss 3T3 fibroblast monolayer 
and a co-culture system was developed. Basal levels of nitrite production from co-
cultures (0 . 5±0 . 05~mol/ml) were approximately, ten fold higher than that of 
cartilage explants alone (0 . 07±0 . 005~mol/ml) . However, there was no significant 
difference between the basal GAGs release from cartilage explants and co-
cultures. 
As in fibroblasts (Fig. 3 .2) and explant cultures (Fig 4.1.2.a), treatment with 10-
20ng/ml of IL-l p induced nitrite production in co-cultures (Fig. 5. 1.1). Treatment 
of co-culture system, with 20ng/ml ofiL-1[3 produced 1.9 ±O . l~mol/ml of nitrite 
on day 1 (Fig. 5.1.1), compared to explants, which produced 0 . 095±0 . 0l~mol/ml 
nitrite under the same conditions (Fig. 4 .1.2.a). Since fibroblasts produced only 
1.5±0 . 1~mol/ml ofnitrite (Fig. 3.2.), magnitude ofthe co-culture response toIL-
lP was thus slightly higher (approximately 10%) than the combined values 
obtained from fibroblast and explant cultures taken alone (Table 6.2a) . 
Like explant cultures, co-cultures produced nitrite and released GAGs in response 
to EPO, with the peak response obtained with 25~U/ml ofEPO. Similarly, EPO-
mediated increase in nitrite production was slightly lower than 20ng/ml IL-l P-
induced production. As in the previous models, combined treatment using EPO 
(25!J.U/ml) and IL-l P (20ng/ml) consistently induced a greater response than 
single treatments alone. This response was of the same order of magnitude to that 
measured in the simple explant model (Fig. 4.4.1d). 
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Like the explant model of RA, the general pattern of nitrite production, over three 
days of co-culture closely resembled with that of GAGs release. Since the GAGs 
do not appear to be produced by fibroblasts monolayer alone (chapter 3) 
increased loss of GAGs were assumed to be a result of fibroblast-mediated 
cartilage breakdown in the co-culture system. Like nitrite production, the 
magnitude of20ng/ml ofiL-1~-stimulated GAGs release (2 . 51 ±0 . 12~-tg/ml) in co-
culture system (Fig. 5.1.2) was also approximately 10-15% higher than IL-1~­
induced GAGs release (2 . 1±0 . 1~-tg/ml) from cartilage explant system (Fig. 4 .1.2c). 
This was the case even with a lower concentration of IL-1 (1 Ong/ml) compared to 
explants, which required 20ng/ml for maximum response. This suggests that IL-
l ~-mediated cartilage breakdown in an explant model was enhanced by 
fibroblasts, which are in turn capable of being stimulated by both IL-l~ and EPO. 
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CHAPTER 6: FINAL DISCUSSION 
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6.0: General discussion 
In many clinical studies to date it has been reported that the use of EPO in RA 
resulted in improvement of both anaemia and disease activity (Kaltwasser et al., 
2001 and Peeters et al. , 1999). The Food and Drug Association approved 
indications for its use are 1) the treatment of anemia associated with chronic renal 
failure; 2) the treatment of anemia related to therapy with zidovudine in HIV 
infected patients; 3) the treatment of anemia in patients with non-myeloid 
malignancies where anemia is due to the effect of concomitantly administered 
chemotherapy; and 4) the treatment of anemic patients scheduled to undergo 
elective, non-cardiac, non-vascular surgery to reduce the need for allogeneic blood 
transfusions, and in patients at high risk for peri-operative transfusions with 
significant, anticipated blood loss. Its use has grown to include a broad range of 
applications outside of the specified clinical settings, including cancer-related or 
cancer treatment-related anemia (such as stem cell transplantation), anemia of 
chronic disease and sickle cell anemia (Rizzo et al. , 2001). 
The most common clinically relevant side effect is hypertension, especially in 
patients with chronic renal failure. Inappropriate erythropoietic stimulation in 
normal persons (e.g. "doping in athletes") may be life threatening. It thickens the 
blood which can overload the heart. There is a high risk of blood clots, strokes, 
heart attacks and death. However, the effects of EPO on cartilage metabolism in 
RA have not been previously investigated. In this study, the effects of EPO on 
cartilage degradation in RA were explored using three model systems. 
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Synovial fibroblasts are a major component of rheumatoid pannus tissue, and they 
are implicated in cartilage degradation associated with RA Therefore, an in vitro 
Swiss 3T3 cell model was established to study the response of rheumatoid 
synovial fibroblasts to EPO (Chapter 3). 
To model the chondrocyte-mediated resorption of cartilage in RA an in vitro 
porcine explant model of cartilage degradation was developed (Chapter 4). In a 
study by Wang et al. , (1997), it was demonstrated that rheumatoid synovial 
fibroblasts co-cultured with articular cartilage slices showed IL-l P-stimulated 
fibroblast invasion of cartilage. In this study, Swiss 3T3 fibroblasts monolayers 
were integrated with the young porcine cartilage explants, and a more complex 
co-culture system was established to model the pannus-cartilage interaction in a 
rheumatoid joint (chapter 5). 
Cartilage degradation was ascertained by measuring cartilage GAGs concentration 
(section 2.5), and nitrite production (section 2.4) was quantified to study the 
response of chondrocytes and fibroblasts to pro-inflammatory stimulus. 
Rotter et al. , (2002), suggested an age-dependent decrease in GAG content of 
human nasal cartilage, possibly due to a decreased metabolic rate. Moreover, 
younger cartilage has been shown to have a rapid rate of metabolic turnover 
(Morales and Hascall, 1989 a). Therefore, it was decided to study the effects of 
IL-l P on both younger (extracted from young pig of approximately of 1-2 month 
121 
old) and older cartilage (extracted from old pig of approximately of 3-4 months 
old), with respect to nitrite production (section 2.4) and GAGs release (section 
2.5). These results were then compared and the young cartilage explants were 
selected to model cartilage degradation (see section 6.1). 
6.1 : Comparison of younger and older cartilages 
The results of nitrite production and GAGs release are compared in table 6.la and 
6.1 b, respectively. 
Cartilage from 3-4 month older pig Cartilage from 1-2 month old pig 
Basal nitrite IL-1-stimualted Basal nitrite IL-1-stimualted 
production nitrite production nitrite 
(JlmoVml) production (Jlmol/ml) production 
(Jlmol/ml) (JlmoVml)/mg 
of cartilage 
0. 092±0. 003 0.094±0.004 0.07± 0.005 0.095± 0.01 
Jlmol/ml JlmoVml JlmoVml JlmoVml 
Table 6.1a: Comparison of basal and IL-1~-mediated (20ng/ml) production of 
nitrite by old (Fig. 4.l.la) and young cartilage explants (Fig. 4.1.2a) into culture 
media. 
The young cartilage explants increased the nitrite production from 0.07± 0.005 to 
0.095± O.OlJlmoVml, in response to IL-l~ treatment. In contrast, IL-l~ failed to 
have an effect on older cartilage explants. This result was in accordance with a 
previous study by Hauselmann et al. , (1998), which showed that superficial layer 
chondrocytes on human articular cartilage are much more responsive to IL-l~ , 
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possibly because they contain more Type-1 IL-l receptors and their 
responsiveness to IL-l f3 decreases with the increase in the age. 
Cartilage from 3-4 month older pig Cartilage from 1-2 month old pig 
Basal release of IL-l f3-stimulated Basal release of IL-l f3-stimulated 
GAG(~g/ml) release of GAG GAG(~g/ml) release of GAG 
(~g/ml) (~g/ml) 
1.13± O.l8J.Lg/ml 1.14± 0 . 07~g/ml 1.0± 0.08J.Lg/ml 2.1±0.1 J.Lg/ml 
Table 6.1b: Comparison of basal and IL-lf3-mediated (20ng/ml) GAGs release 
from old (Fig. 4.l.lc) and young cartilage explants (Fig. 4.1.2c) into culture 
media. 
Unlike older cartilage explants, following treatment with IL-l {3, younger cartilage 
explants had statistically significant (p<O.OOl) release of GAG, compared to 
control. In both, old and young cartilage explants, IL-113 did not affect the GAG 
content of cartilage. However, the GAG content of old cartilage explant digests 
was approximately 750~g/ml/mg (see Fig. 4.l.lb), and this value was 
significantly lower (P<O.OOI) than the GAG concentration of young cartilage 
digests (Fig. 4.1.2 b), which was measured to be approximately llOO~g/mVmg. 
This study revealed that only 20% of GAGs from young cartilage were lost into 
culture media on day 6 compared to day 0 under untreated control conditions (see 
Fig. 4.1.2c). Whereas, in older cartilage, by day 6 approximately 75% of GAGs 
, were lost into culture media under similar untreated control conditions (see Fig. 
4.1.1 c). Therefore, based on these observations, it was decided to select younger 
cartilage explants as an explant model of cartilage degradation. This younger 
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cartilage explant model was integrated with fibroblast monolayer to establish a co-
culture modeL The three models are compared as follows:-
6.2: Comparison of in vitro models 
The response of each in vitro model system to IL-1 ~ and EPO, with respect to 
nitrite production and GAGs release was investigated and compared, (see table 
6.2a and 6.2b, respectively). 
Stimulants Swiss 3T3 Porcine cartilage Porcine cartilage 
model explant model explant co-
culture model 
Control 0.46±.0.03 0. 072±0. 004 0.60±0.08 
J..Lmol/ml J..Lmol/ml J..Lmol/ml 
IL-1~ 1.5±0.08 0.095±0.01 1.78±0.08 
20ng/ml IJ.mol/ml IJ.mol/ml IJ.mol/ml 
EPO 0.58±0.02 0.09±0.006 1.65±0.07 
25J..LU/ml J..Lmol/ml J.Lmol/ml J..Lmol/mJ 
EPO & 1.82±0.05 0.12±0.007 2. 1±0.07 
IL-l IJ.mol/ml J..Lmol/ml IJ.mol/ml 
Table 6.2a: The values of nitrite production corresponding to day 1 of the time 
course studies in each modeL A similar pattern of nitrite production was noticed 
on the rest of the days during time course studies. 
Co-culture explant model, following treatment with IL-l~' produced higher levels 
of nitrite (1.78±0.08 j.lmol/ml, see Fig. 5.3.1) as compared to the combined 
response of porcine cartilage explant (0.095±0.01J..Lmol/ml, see Fig. 4.1.2a) and 
Swiss 3T3 cell models, to IL-l~ treatment (1.5±0.08j..imol/ml, see Fig.3.2). 
Likewise, in this model the magnitude of EPO-mediated nitrite production 
(1.65±0.07j..imol/ml, see Fig. 5.3 .1) was also higher than the sum of the EPO-
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mediated nitrite production by both porcme cartilage explant 
(0.09±0.0061J.mol/ml, see Fig. 4.4 .1b) and Swiss 3T3 fibroblasts models 
(0.58±0.021J.mol/ml, see Fig. 3.3.1c). These findings suggest that presence of 
fibroblasts in the co-culture model enhanced the IL-l P and EPO-mediated 
production of nitrite. 
Stimulants Swiss 3 T3 model Porcine cartilage Porcine cartilage 
explant model explant co-culture 
model 
Control No response 1.4±0.171J.g/ml 1. 5±0. 1 f.lg/ml 
IL-IP No response 2.0±0.l!J.g/ml 2. 51 ±0.121J.g/ml 
20ng/ml 
EPO No response 1. 9±0. l!J.g/ml 2.4±0.l!J.g/ml 
251J.U/ml 
EPO & No response 3.2±0.4f.lg/ml 3.6±0.051J.g/ml 
IL-IP 
Table 6.2b: The values of GAGs release corresponding to dayl of the time course 
studies in the each model system. A similar pattern of GAGs loss was seen on 
other days during time course studies 
Like nitrite production, the levels of GAGs release from cartilage matrix were 
elevated, by approximately 5-10%, under the influence of Swiss 3T3 fibroblasts, 
following treatment with IL-IP and EPO. The findings from this study suggest 
that activated synovial fibroblasts, as part of a complex cellular network, may play 
an important role in the pathogenesis ofRA. 
The explant model demonstrated a significant increase in the production of nitrite, 
following a combination treatment with IL-IP and EPO (0.12±0.0071J.mol/ml), as 
compared to IL-IP (0.09±0.006f.lmol/ml) and EPO (0.095±0.0lf.lmol/ml) 
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treatments alone (Fig. 4.4.1c and table 4.4.1c). This shows that, EPO may 
modulate IL-1~-induced production of nitrite via activation of NOS . In a study by 
Benergee eta/., (2001), it was demonstrated that exposure of endothelial cells to 
EPO may induce NOS activity. Therefore, it was speculated that the exposure of 
cartilage chondrocytes to EPO in the presence ofL-Name, (100!-J.M) would inhibit 
EPO-induced nitrite production. 
The EPO-induced nitrite production by porcine cartilage explants was inhibited 
(see Fig. 4.4.1e and table 4.4.1e), following treatment with L-Name, 1 00~ 
which suggested NOS activity. A possible mechanism through which EPO 
stimulates NOS activity may be by inducing the expression of iN OS gene, which 
leads to the synthesis of iN OS enzyme that produces NO from L-arginine. 
In porcine cartilage explant model, L-NAME had no significant effect on basal 
GAGs release from the cartilage. However, it inhibited (p<O.OS) IL-l~ and EPO-
mediated GAGs release from the cartilage compared to IL-l~ and EPO treated 
groups, but this effect was not consistent over 3 days (see Fig. 4.4.1f and table 
4.4.1£). L-Name significantly (p<O.OOl and p<O.Ol) inhibited the release of GAGs 
from the cartilage, on stimulation with EPO combined with IL-l~ on day 2 and 3, 
respectively. This implies that NOS-activated NO production, is at least partially 
involved in EPO and IL-l ~-mediated GAGs release from cartilage. In contrast to 
its effect on porcine cartilage explants, L-Name failed to have an effect on co-
cultured explants. 
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6.3: Mechanism of action of EPO 
The optimum concentration ofEPO (25~U/ml) required to induce a response was 
the same in each model studied in this investigation. This specific concentration 
ofEPO would bind completely to specific EPOR cell surface receptors to induce a 
response. Similarly a range of lower concentrations (0.1, 1, lO~U/ml) would not 
be enough to bind and initiate a response. Likewise, at a higher concentration the 
EPO molecules would inactivate the receptors by competing with each other to 
interact with the cell surface receptors. 
In the fibroblast monolayer model, a statistical significant (p<O.OOl) difference in 
EPO-induced nitrite production was measured as compared to IL-l P-induced 
production (see Table 3.3.1c). This suggests that EPO may be a less potent 
stimulus of inflammation compared to IL-JP in this 3T3 cell model. However, 
both cartilage explant and co-culture models revealed that EPO (25~U/ml) may be 
as potent as IL-l p (20ng/ml) with respect to cartilage breakdown. This suggests, 
there may be a similarity between the structure of the two cytokines, and that they 
may follow a similar signal transduction pathway. 
Analysis ofthe structure ofEPO has revealed that, it is a long chain cytokine with 
a short-chain cytokine topology, which is composed of four helical bundles 
(Appendix IV.) (Cheetham et al., 1998). However, comparison with the structure 
of IL-IP, that possess a P-trifol 12-stranded P-barrel structure, has shown that 
there does not exist any similarity between the structure of two cytokines 
(Appendix V) (Finzel et al. , 1989). 
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The identification of intracellular signalling pathway followed by EPO would help 
understanding the mechanism of the action of EPO. This study suggests a very 
narrow range of concentrations of IL-l p and EPO induce effects of cartilage 
degradation, and it can be speculated that their mechanism of action is under fine 
regulation. However, it is clear from the observed effects that the mechanism of 
action for both cytokinesis very similar. 
6.4: Further Research 
It has been shown that signal transduction pathways leading to the production of 
NO are activated by a number of factors such as environmental stresses of 
osmotic, UV radiation and heat shock, and pro-inflammatory cytokines. Badger et 
al. , (1998) reported that, pyridinyl imidazole SB 203580, a specific p38 MAP 
kinase inhibitor, could inhibit chondrocyte-mediated NO production and caused a 
significant suppression of adjuvant-induced arthritis by blocking p38 MAP kinase 
pathway. The signal transduction pathway activated by EPO that leads to the 
production of NO can be identified using Mitogen-activated protein kinase 
(MAPK) specific inhibitors. Therefore, p38 MAP kinase pathway can be targetted 
by using SB 203580, to determine whether it would suppress EPO-induced nitrite 
production. 
The findings by Han et al. , (2001), suggested that activation of JNK is implicated 
in MMP expression and joint destruction in RA. In that study, a JNK inhibitor 
SP600125 (anthra [1 ,9-cd] pyrazol-6 (2H)-one) was employed to rat adjuvant-
induced arthritis and a decreased rat paw swelling was noticed. In addition, it 
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completely inhibited radiographic damage that was associated with collagenase-3 
gene expression. Therefore, SP600125 could be employed to see whatever it 
would inhibit the EPO-mediated GAG release and consequent breakdown of 
cartilage. In order to gain an in depth knowledge of EPO-mediated catabolic 
activity occurring within the cartilage the net synthesis of cartilage GAGs can be 
measured, using sulphate incorporation assay. 
To further examine the effect of EPO on cartilage degradation in RA, the data 
obtained with porcine explant model should be repeated on human arthritic 
cartilage explant model. This would give a more detailed understanding of the 
effect ofEPO on human cartilage metabolism in RA. 
The post-culture cartilage explants can be investigated for the expression of 
EPOR, following incubation in the presence of EPO, using Western Blotting 
techniques. This would provide new insights into development of antagonists for 
therapeutic use. 
6.5: Conclusion 
The findings from this thesis produced several key conclusions about the use of 
fibroblast monolayer, porcine explant and co-culture systems as in vitro models of 
RA. The simple fibroblast monolayer system was employed to model the response 
of rheumatoid synovial fibroblasts to EPO. The use of cartilage explants in an in 
vitro system provides a picture of chondrocyte activity in response to EPO, 
however, these observed functions may be modified on interaction with 
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fibroblasts, as demonstrated by studies usmg a complex co-culture system 
(chapter 5). The co-culture model would provide a potential system to evaluate 
the effect of other factors, such as the production and secretion of MMP, and 
secondary cytokines. 
The results from this novel study revealed that EPO indeed cause an increase in 
the catabolic activity of cartilage, which was enhanced following incorporation 
with fibroblasts . Unfortunately, no data is available that suggests a correlation 
between the EPO-treated anemia and the development of musculo-skeletal 
problems. However, findings from this study suggest that clinical administration 
ofEPO to treat anaemia and its illegal usage by athletes may lead to development 
of arthritis in later life. The findings of this study provide a plausible mechanism 
for the observation that athletes participating in contact sports or activities, such 
as excessive running, who are at a higher risk of early development of OA, 
enhance this risk still further following consumption of EPO. The current study 
concludes that presence of EPO can directly influence cartilage degradation 
through the release of GAGs and NO and that it may have synergistic and additive 
effects with pro-inflammatory cytokines such as IT.,- I f3 and may potentiate joint 
inflammation. 
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Appendix I 
Effect of EPO on nitrite production by Swiss 3T3 fibroblasts over a 3 day 
:::!: 
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Appendix 1: Time course of nitrite production by Swiss 3T3 fibroblasts (n=6) 
in tissue culture supernatant was measured during a 3 day period at 24 hour 
intervals following treatment 0.1,1 and 10J..1.U/ml EPO. 
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Appendix ll 
Effect ofEPO (0.1, 1 & 10J.1U/ml) on nitrite production into the culture 
media by porcine cartilage explants during a 3 day time course 
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Appendix ll: Cartilage was isolated from porcine noses (n=8) and pre-cultured in 
vitro for 24 hours prior to addition of EPO 0.1, 1 and 1 OJ.!U/ml. Culture media was 
quantified for nitrite production following 3 days of culture. 
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Appendix ill 
Effect ofEPO (0.1, 1 & 10 J.LU/ml) on GAGs released into the culture 
media from porcine cartilage explants during a 3 day time course study 
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Appendix ill: Cartilages were isolated from porcine noses (n=8) and pre-
cultured in vitro for 24 hours prior to addition ofEPO 0.1, 1 and 1 Oj..t.U/ml. 
Culture media was analysed for GAGs released following 3 days of culture. 
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Appendix IV 
NMR Structure ofErythropoiten taken from Protein Data Bank (Cheetham et 
a!., 1998) 
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Appendix V 
Crystal Structure of recombinant human interlu.k:in-1 beta taken from Protein 
Data Bank (Finzel et a/. ,1989) 
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Appendix VI: Associated Publication 
Baig S, Patel Y. , Coussons P . and Grant R. (2002) Erythropoietin and lnterleukin-
1~ modulate nitrite production in a Swiss 3T3 cell model of rheumatoid synovial 
fibroblasts. The Biochemist; 24: 32-33. (Abstract) 
Baig S, Patel Y. , Coussons P. and Grant R. (2002) Erythropoietin and lnterleukin-
1~ modulate nitrite production in a Swiss 3T3 cell model of rheumatoid synovial 
fibroblasts. The Biochemist; 30(6): 883-886. (Research paper) 
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